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Abstract
The development of manufacturing processes for biopharmaceuticals is carried out 
by performing experiments in the laboratory and then the pilot plant. These 
laboratory -  scale experiments are often misleading as they do not allow for the 
effect of the large-scale processing environment on the properties of biological 
process material. The research contained within this thesis seeks to develop 
laboratory techniques capable of eliciting the effects of the processing environment 
on the material and of predicting the performance of large-scale unit operations used 
in the purification of monoclonal antibody (MAb) biopharmaceuticals using 
milliliter volumes of process material. Two key interactive stages were examined; 
firstly, an early centrifugation clarification stage designed to prepare material for 
subsequent filtration which precedes the second stage studied, a high affinity 
antibody capture step. The first focuses on the whole cell broth, containing the 
contaminants and the antibody product, the latter on the antibody product itself. A 
scale-down centrifuge technique which employed a rotating-disc, centrifuge feed 
zone mimic along with a laboratory-scale centrifugation method were developed to 
predict the clarification performance of two pilot, disc stack centrifuges with 
differing feed zone configurations and a manufacturing-scale disc stack centrifuge. 
The material obtained from the scale-down centrifuge protocol was shown to be 
equivalent to that from one of the pilot centrifuges to which it had been compared 
and, hence, could be used for the development of subsequent unit operations, such as 
chromatography processes. A method was developed to predict the elution profile of 
an 18 L pilot affinity chromatography column using a scale-down column with a 
column volume of one milliliter. A regime analysis of the laboratory-scale
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chromatography system was performed using conductivity transitions to determine 
the extent of additional zone broadening occurring at the small scale so that the 
prediction of the large-scale elution volume and eluting product concentration could 
be significantly improved.
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Chapter 1 - Introduction
Lonza Biologies is a contract manufacturer of therapeutic proteins derived 
from animal cell culture. The majority of the processes operated are for the 
production of monoclonal antibody therapeutics. A typical production process can be 
divided up into three phases (Figure 1.1). During the cell culture phase, animal cells 
are grown in suspension culture and secrete the protein product into the surrounding 
growth medium. At the end of the cell culture, the material generated is clarified by 
processing through centrifuges (that remove most of the cells and cell debris) and 
filters (that remove any remaining solids) giving a clarified broth that can be purified 
in the final phase of the process. A typical purification process utilizes two or three 
chromatography columns with associated ultrafiltration steps that remove impurities 
such as proteins and nucleic acids produced by the cells along with the product.
Cell Culture
Clarification
centrifuge
filters
Purification
chromatography
ultrafiltration
Figure 1.1. Overview of a therapeutic protein production process
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Process development scientists seek to develop manufacturing processes that yield 
products that meet pre-defined criteria of safety and effectiveness. Development 
studies must be completed within short timelines (to allow early market entry of the 
product enabling the product’s sponsor to recoup drug development costs), give a 
robust process to ensure product safety and minimise the risk of batch failure and 
provide an optimised process that minimises Cost of Goods.
Conventional development methods have been used successfully in the past 
to bring products to the market. They use scale-up methodologies based on 
established theory and hence both industry and regulators are comfortable with these 
approaches. However, they typically require large amounts of product/process 
material to yield relatively small amounts of process information and are often 
poorly predictive o f the performance of large-scale processes. For example, 
centrifugation process development to identity an operating flow rate that gives the 
target level of process stream clarification while maximising plant throughput 
necessitates a 500 L cell culture to generate sufficient material for the development 
experiment, which is both costly and time consuming. Further, pilot-scale 
centrifugation studies can over-predict the clarification performance of large-scale 
equipment due to critical differences between the hydrodynamic environment of the 
equipment at the two scales and its impact on shear-sensitive process materials. 
Novel technology is required that permits more rapid manufacturing process 
development with reduced material requirements. This would allow more 
information and greater process understanding to be acquired which, in turn, will 
lead to more robust and optimised processes being developed in a shorter timeframe.
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The aims of the work contained within this thesis were as follows,
• To develop and verify a centrifuge process development tool requiring small
volumes of process material capable of predicting the performance of large- 
scale equipment.
•  To develop and verify a chromatography process development tool capable
of using the material generated by the centrifugation tool and capable of 
predicting the performance of large-scale columns.
• To develop appropriate models and visualisation tools to facilitate the use of
the data generated by the process development tools for process design.
21
Literature Review 
1.1. Antibodies
Antibodies or immunoglobulins are soluble proteins produced by the immune system 
of vertebrates to recognize and initiate the destruction of foreign molecules such as 
those derived from microorganisms. Any given antibody molecule has a specific 
affinity for the foreign macromolecule that stimulated its synthesis. Macromolecules 
capable of eliciting an antibody-producing response by the immune system are called 
antigens and include proteins, polysaccharides and nucleic acids. An antibody will 
recognize a highly specific site on an antigen molecule called an epitope.
1.1.1. Antibody structure
Antibodies typically share a common Y-shaped structure consisting of four 
polypeptide chains: two identical heavy chains that each carry covalently-attached 
oligosaccharide groups; and two identical, non-glycosylated light chains. The two 
heavy chains are joined together by disulphide bonds that are located in a flexible 
region of each polypeptide called the hinge. The hinge is typically 12 amino acid 
residues long and is exposed to both enzymatic and chemical cleavage. A single 
disulphide bond joins each of the light chains to one of the heavy chains.
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Figure 1.2. The structure of a human antibody (IgG) showing the ‘Y’-shaped 
structure, the location of the heavy and light chains, the disulphide bridges (-s-s-), 
the antigen binding site, the antibody-binding fraction (F ab) and the crystalizable 
fraction (Fc) and the various domains (C h 1 -3, V h & V l , C l). Reproduced from 
Sommerfeld & Strube, 2005.
Antibody light chains contain around 214 amino acids and have a molecular weight 
of around 25 kDa. The light chains consist of two domains, a variable domain ( V l) at 
the N-terminus (amino acid residues 1 to 108) which exhibit considerable amino acid 
residue sequence variability between different antibodies and a constant domain (C l) 
at the C-terminus (residues 109-214) which has a highly conserved amino acid 
sequences. The heavy chains consist of 446 amino acid residues that fold into four 
domains and have a molecular weight of approximately 50 kDa. As with the light 
chain the residue sequence of the N-terminal domain varies between antibodies and 
is 109 amino acid residues in length (V h). Three sequences within the variable 
domain of the light chain and three within the variable domain of the heavy chain
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exhibit far greater residue variability than other sequences within these domains. 
These, so called, hypervariable segments form the epitope-binding site and antibody 
specificity is determined by the nature of amino acid residues contained within them. 
The three remaining constant domains at the C-terminus of the heavy chain are of 
equal size and have conserved amino acid residue sequences (Ch 1, 2 & 3) to one 
another and to the constant domain of the light chain.
Cleavage of the antibody at the hinge region yields three proteins two of which bind 
antigen and are known as Fab fragments (ab is an abbreviation of ‘antigen binding’) 
and one that does not bind antigen and is known as the Fc fragment because a 
solution of these fragments will crystallize readily. F& fragments are composed of 
the entire light chain of the antibody bound to the N-terminal half of the heavy chain. 
The Fc fragment consists of the C-terminal half of the heavy chain consisting of the 
seconds and third constant domains. The role of the Fab section of the antibody is to 
bind antigen and hence each antibody is bivalent while the Fc region is responsible 
for mediating protective responses known as effector functions such as compliment 
fixation which ultimately lead to pathogen lysis.
1.1.2. Antibody classes
There are five classes antibody IgG, IgM, IgA, IgD and IgE. The constant regions of 
the heavy chains vary from one class to another and give each class distinct 
biological characteristics.
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IgM is composed of five of the monomeric units described above giving each IgM 
molecule ten antigen binding sites and allowing them to bind tightly to antigens 
containing multiple identical epitopes. They are the first antibody to be produced in 
an immune response but have lower affinity for antigens than antibody classes 
subsequently produced.
IgG is the principal antibody in the serum while IgA is the major class of antibody in 
external secretions such as saliva, tears, bronchial mucus and intestinal mucus where 
it forms dimers of monomeric units. IgA acts as the first line of defense against 
bacterial and viral antigens. IgG and IgA can further be divided into subclasses that 
result from minor differences in the amino acid sequence of the heavy chain. In 
humans there are four subclasses of IgG and two subclasses of IgA.
IgD is found in low levels in serum where its roles is uncertain, however, it is also 
found on the surface of B cells where it acts as an antigen receptor.
IgE is important in providing protection from parasites. Binding of IgE antibodies to 
an antigen leads to the degradation of mast cells and the release of a number of 
agents including histamine that induce smooth muscle contraction and the secretion 
of mucus (Stryer, 1995).
1.1.3. Polyclonal antibodies
When infected by a pathologic agent a host organism’s immune response will 
generate a large number of different antibodies that recognize different antigens and
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different epitopes on an individual antigen. Each antibody is produced from an 
individual clone of white blood cell called plasma cells. Serum from immunized 
animals is a good source of polyclonal antibodies which can be used as reagents in 
immunochemical techniques. Polyclonal antibody containing sera from rodents 
immunized with infectious agents has been used for therapeutic purposes in humans; 
however, such crude preparations were ineffective and the rodent serum itself 
produced an adverse immune reaction in patients. More notably, polyclonal antibody 
therapeutics have been used as neutralizing venoms for the treatment of snake-bite 
victims (http://www.protherics.com/. 2005).
1.1.4. Monoclonal antibodies
In 1975, Georges Kohler and Cesar Milstein invented hybridoma technology and 
were later awarded the Nobel Prize. A hybridoma is created by fusing an antibody- 
producing plasma cell from an immunized rodent with a cell derived from a rodent 
myeloma tumour (Kohler & Milstein, 1975). Such hybrid cells can be cloned and 
cultured indefinitely and, along with advanced cell culture techniques, allow the 
mass production of individual murine monoclonal antibodies.
1.1.5. Therapeutic monoclonal antibodies
Monoclonal antibodies can be raised against a vast number of epitopes including 
those contained within antigenic proteins involved in causing disease. By generating 
and then mass producing antibodies that could be administered to patients it 
appeared, in the 1980’s, that modem medicine had discovered its ‘Magic Bullets’,
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capable of binding to disease-implicated proteins with high specificity and bringing 
about their destruction. Such therapeutics, it was believed, would be ideal for 
identifying and destroying cancerous cells which frequently express tumour-specific 
antigens. An example of one such monoclonal antibody is trastuzumab
T W
(Herceptin ), marketed by Genentech, which targets and blocks a growth receptor 
on the surface of breast cancer cells. In a clinical trial consisting of 469 women with 
late stage breast cancer and testing positive for the receptor, a combination of 
Herceptin™ and a standard chemotherapeutic agent reduced the size of tumours and 
led to an average increase in life expectancy of 5 months (Slamon et al., 2001). The 
effectiveness of monoclonal antibody therapies can be increased by attaching toxins 
or radionucleotides. For example, IDEC Pharmaceuticals’ radio-antibody, 
ibritumomab tiuxetan (Zevalin™) was approved by the US Food and Drug 
Administration in February 2002 for the treatment of non-Hodgkin’s lymphoma. 
FDA approved monoclonal antibody therapies, their degree of humanization, 
indication, company and approval date are shown in Table 1.1
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Product Type Indication Company Approved
Muromonab
-CD3 Murine
Transplant
rejection
Johnson & 
Johnson 1986
Abciximab Chimeric Cardiovasculardisease Centocor 1994
Rituximab Chimeric B-cell lymphoma Genentech 1997
Daclizumab Humanized Transplantrejection
Hoffmann-La
Roche 1997
Basiliximab Chimeric Transplantrejection Novartis 1998
Palivizumab Humanized Respiratory syncytial virus Medlmmune 1998
Infliximab Chimeric
Rheumatoid 
arthritis/ 
Crohn’s Disease
Centocor 1998
Trastuzumab Humanized Breast cancer Genentech 1998
Gemtuzumab-
ozogamicin Humanized
Acute myeloid 
leukaemia Wyeth 2000
Alemtuzumab Humanized Chronic leukaemia Genzyme 2001
Ibritumomab Chimeric Non-Hodgkin’sleukemia Biogen IDEC 2002
Adalimumab Human Rheumatoidarthritis Abbott 2003
Omalizumab Humanized Allergic asthma Genentech 2003
Tositumab-1131 Murine Non-Hodgkin’sleukemia Corixa 2003
Efalizumab Humanized Moderate to severe psoriasis Genentech 2003
Cetuximab Chimeric Various cancers Imclone 2004
Bevacizumab Humanized Various cancers Genentech 2004
Natalizumab Humanized Multiple sclerosis Biogen Corp 2004
Etanercept Fusion RheumatoidArthritis Immunex 1998
Alefacept Fusion Chronic plaque psoriasis Biogen Corp 2003
Table 1.1 showing FDA approved monoclonal antibody therapies, their degree of 
humanization, indication, company and approval date.
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1.1.5.1. Murine monoclonal antibodies and the HAMA response
Initial optimism over therapeutic monoclonal antibodies was met with limited 
clinical success as murine monoclonal antibodies were found to be antigenic in 
humans. Patients who received these therapeutics frequently developed immune 
responses to the drugs and produced human anti-mouse antibodies (HAMA) to these 
murine molecules which their immune systems recognized as foreign. The HAMA 
response led to the destruction of the therapeutic antibody, thereby reducing drug 
effectiveness (Winter & Milstein, 1991). Furthermore, murine monoclonal 
antibodies were found to be ineffective at triggering human effecter cells, such as the 
macrophages required to destroy the antibody-antigen complex, due to subtle 
differences between the heavy chains of murine and human antibodies. Of the 
murine antibodies only muromonab-CD3 (OKT-3™), sponsored by Ortho Biotech 
and marketed by Johnson & Johnson, has been approved by the US Food and Drug 
Administration for the reversal of acute rejection of kidney transplants. Muromonab- 
CD3’s mechanism of action involves targeting a glycoprotein on the surface of T- 
cells in the immune system thereby preventing them from recognizing the 
transplanted organ as foreign. The success of this product lies not only in the fact 
that the product shuts down part of the immune system which could clear the drug 
but also that patients undergoing kidney transplants are treated with 
immunosuppressive drugs and are subsequently less likely to generate the HAMA 
response (Guru, 2002).
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1.1.5.2. Chimeric monoclonal antibodies
Chimeric antibodies are genetically engineered by constructing genes in expression 
vectors that contain mouse and human DNA sequences. The resulting translated 
protein has human constant domains with murine variable domains (Morrison et al., 
1984; Boulianne et al., 1984). The human constant regions are capable of 
communicating with patients’ immune systems while the proportion of antigenic 
murine sequences is significantly reduced. The application of chimeric antibody 
technology led to a number of new products being approved such as abciximab 
(Reopro™), sponsored by Centocor, which reduces the risk of blood clots in patients 
suffering from cardiovascular disease by targeting receptors on the surface of 
platelets and rituximab (Rituxan™), sponsored by Genentech, for the treatment of 
non-hodgkins’ lymphoma.
1.1.5.3. Humanized and human antibodies
To further improve the effectiveness of monoclonal antibody therapies, research 
continued into reducing the proportion of murine sequences in the protein. In 1986, 
Greg Winter, working at Cambridge University, reduced the mouse component of 
chimeric antibodies to between 5 and 10 % by replacing the entire murine gene with 
human DNA sequences except for those sequences that code for the hypervariable 
regions of the epitope binding site (Jones et al, 1986). Such humanized antibodies 
evaded patients’ immune systems and a number have since been approved by the 
FDA, the first of which, daclizumab (Zenapax™), was approved in 1997 and binds 
to and inhibits a receptor on activated white blood cells which would otherwise
30
stimulate tissue rejection of transplanted organs. In 2003 adalimumab (Humira™) 
became the first human antibody to be approved by the FDA for therapeutic use and 
was created using phage display technology. The process of phage display 
technology involves the harvesting of genes that code for antibody variable regions 
from populations of lymphocytes and cloning them for display of the associated 
heavy and light chain variable domains on the surface of viruses that infect bacteria 
or bacteriophage. Bacteriophage expressing proteins with the desired specificity and 
affinity can be selected by antigen affinity techniques and then further improved by 
mutation allowing a desired human antibody to be produced without any need for 
immunization (Winter et al., 1994).
1.1.5.4. Fusion proteins
T'\ /  TXyff
Etanercept (Enbrel ) and alefacept (Amevive ) are both FDA approved 
recombinant fusion proteins that contain antibody constant domains that are required 
for product functionality. The Fab regions of the antibody molecule are replaced with 
a protein such as the Tissue Necrosis Factor (TNF) receptor component of Enbrel™ 
(http://www.enbrel.com/). Fusion proteins are manufactured in a similar way to 
monoclonal antibodies.
1.2. Manufacturing therapeutic monoclonal antibodies
Annual production of therapeutic monoclonal antibody products is small when 
compared to small molecule drugs due both to the specific and potent nature of 
antibody therapeutics. Demand varies considerably between products; however, even
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for a more common indication such as rheumatoid arthritis production is unlikely to 
exceed 500 kg per annum equivalent to 100,000 patients being administered 5 grams 
of antibody per annum. Production costs are also typically much higher than small 
molecule therapeutics which can be synthesized for approximately US$ 5 per gram 
while antibody drugs incur production costs of US$ 100-1000 per gram. The 
relatively low volume of product required by the market allows demand to be met 
through campaigns of batch production while simultaneously minimizing the risks, 
such as contamination, of operating a continuous process. Commercial production 
processes for the large-scale manufacture of monoclonal antibodies are typically 
divided into three main phases. During the first phase, mammalian cells capable of 
expressing the desired antibody are grown in culture and secrete the product into the 
surrounding growth medium. Secondly, the product-containing growth medium is 
recovered by removal of the cells and finally the product is purified from impurities 
within the growth medium.
1.2.1. Cell culture
A characteristic of monoclonal antibody production along with the manufacture of 
other recombinant proteins is that the product is produced using living organisms 
grown under controlled conditions. The majority of full length therapeutic antibodies 
are produced in mammalian cell lines (Anderson & Reilly, 2004) because of their 
capacity for proper folding, assembly and post-translational modification of the 
product (Wurm, 2004). Table 1.2 below shows the cell culture methods used in the 
production of seven licensed therapeutic monoclonal antibodies.
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Antibody Cell Line Format Suspension or attached Medium
Etanercept 
(Enbrel ) CHO
Stirred tank 
bioreactor Suspension Not revealed
Trastuzumab
(Herceptin™) CHO
Stirred tank 
bioreactor Suspension
Serum-free,
Gentamicin
containing
Infliximab
(Remicade™)
Murine
Myeloma
Stirred tank 
bioreactor, 
perfusion 
with spin 
filter
Suspension
Serum-free, protein 
hydrolysates, 
bovine transferrin, 
insulin, serum 
albumin
Palivizumab
(Synagis™) NSO
Stirred tank 
bioreactor, 
fed-batch
Suspension Serum-free
Basiliximab
(Simulect™)
Murine
Myeloma
Stirred-tank
bioreactor,
perfusion
Suspension Serum-free
Daclizumab
(ZenapaxTm) SP2/0
Not
revealed Not revealed Not revealed
Rituximab
(Rituxan™) CHO
Stirred-tank
bioreactor Suspension
Contains
Gentamicin
Table 1.2 showing cell culture methods used in the production of seven approved 
therapeutic monoclonal antibodies (adapted from Chu & Robinson, 2001).
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1.2.1.1. Cell lines
Although monoclonal antibodies were originally produced in hybridoma cells 
(Kohler & Milstein, 1975) regulatory approval has been gained for recombinant 
protein production in immortalized Chinese hamster ovary (CHO), mouse myeloma 
(NSO & Sp2/0), monkey kidney (COS), baby hamster kidney (BHK), human embryo 
kidney (HEK-293) and human retinal cells (PER-C6) (Wurm, 2004). The choice of 
cell line for production is usually based on the ability of the line to produce product 
with human-like glycosylation patterns, to express the product in a stable fashion 
following gene insertion and to achieve high specific production rates (Sommerfeld 
& Strube, 2005). CHO and mouse myeloma cells fulfill these criteria well and hence 
are frequently used cell lines (see Table 1.2). These cell lines produce product with 
near human glycosylation patterns, stably express the protein and are capable of 
achieving final product concentrations of 4.7 g.L'1 (Wurm, 2004). Both the culture 
and genetic manipulation of these cell lines have been extensively studied permitting 
considerable cell culture process control (Peakman et al., 1994). Genetic 
manipulation of cell lines can be carried out in order to confer on the cell lines 
properties enabling improved bioreactor performance such as controlling cell growth 
(Bi et al., 2004) (Chiang & Sisk, 2005), preventing cell death (Ibarra et a l, 2003) or 
influencing glycosylation (Shields et al, 2002).
1.2.1.2. Cell culture media
High antibody titre cell culture processes are a result, in part, of the considerable 
research undertaken to optimize the growth media that provides cells with the
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necessary compounds required for growth. Commercially available media can be 
obtained from suppliers; however, leading recombinant protein manufacturers 
develop and optimize their own formulations which are valuable commercial secrets. 
More than one media will be used in a single manufacturing process each tailored to 
a specific phase. For example, production media which is used for up to 21 days in 
the large-scale bioreactor is unlikely to be the same as that used for the sub­
cultivation of rapidly growing cells lasting only 3-5 days that takes place in seed 
bioreactors. Media development is important for the productivity of the process and 
is carried out for each process and cell line. In the past fetal bovine serum was 
required for mammalian cell culture and added at a concentration of 1-20%. Serum 
contains peptides, growth factors, proteins, lipids, carbohydrates and small 
molecules that promote cell growth; however, modem media formulations support 
growth in the absence of serum. Using serum-free media reduces the cost of the 
media, the risk of transmission of adventitious agents such as prions and the cost of 
purifying the product (Wurm, 2004) hence manufacturers of antibodies prefer to use 
chemically defined media containing essential amino-acids, trace elements and 
proteins (Moran et a l, 2000). However, cell lines frequently require adapting to 
growth in the absence of serum which is a time consuming process and frequently 
leads to a reduction in the specific productivity of the cell line (Sommerfeld & 
Strube, 2005). Cell culture is possible in completely protein-free media (Hamilton & 
Ham, 1977) leading to further decreases in purification costs as the product is at least 
twice as pure as that produced in a protein-containing culture media (Sommerfeld & 
Strube, 2005).
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1.2.1.3. Recombinant protein expression systems
Cell lines are genetically engineered to express the required therapeutic antibody by 
transfecting the cells with foreign DNA containing the gene encoding the protein 
product. To maximize cell culture productivity a stable expression system is required 
that ideally fulfils two criteria. Firstly it should be selective and hence will not 
permit non-product producing cells to grow and secondly it should be stringent in 
that it favours the growth of cells with high specific production rates. One common 
expression system is the glutamine synthetase (GS) system licensed to Lonza 
Biologies (Brown et a l, 1992). Glutamine synthetase is an enzyme that catalyses the 
synthesis of glutamine from glutamate and ammonium. Mammalian cells have no 
other mechanism for producing this essential and unstable amino acid. Mouse 
myeloma cells such as NSO cell lines are unable to produce sufficient glutamine 
synthetase to grow in media that does not contain glutamine. If the genes encoding 
the product and glutamine synthetase enzyme are incorporated into the same 
segment of DNA only cells containing the gene encoding the product will be able to 
grow in glutamine free media. Although CHO cells produce sufficient endogenous 
glutamine synthetase to permit growth in glutamine free media the specific 
glutamine synthetase inhibitor methionine sulphoximine (MSX) can be used at 
concentrations of 10-100 pM to limit the enzymes activity so that only transfected 
cells with additional enzyme activity through vector amplification are capable of 
survival (Barnes et a l, 2000). A further advantage of the glutamine synthetase 
system is that transfected cells metabolize ammonia in the media, a toxic and 
unwanted by-product of cell growth (http://www.lonza.com/. 2005).
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An alternative to the glutamine synthetase system is the dihydrofolate 
reductase (DHFR) system. DHFR is an enzyme, the activity of which is blocked by 
exposing cells to the drug methotrexate (MTX) (Gandor et al., 1995). Most cells 
exposed to MTX will die; however, a small proportion that overproduce DHFR will 
survive. If the concentration of MTX is steadily increased over successive cell 
generations surviving cells can contain a few thousand copies of the length of DNA 
encoding product and DHFR enzyme (Wurm et al, 1986). Most cells in which 
amplification has occurred produce more recombinant protein than those cells in 
which it has not and the improvement of specific productivities can be 10- to 20-fold 
(Zettlmeissl et al,. 1988).
1.2.1.4. Bioreactor formats
Historically mammalian cell culture was carried out using cell lines that grew while 
attached to a solid support such as the surface of a roller bottle or porous 
microcarrier beads. Today many cell types have been adapted to grow in suspension 
culture facilitated by the use of shear-protecting agents such as Pluronic F68 (van der 
Pol & Tramper, 1998). Suspension cell culture processes now dominate processes 
for the production of recombinant proteins as the scaling parameters are well 
understood and process control is facilitated in a homogeneous system (Chu & 
Robinson, 2001). Both stirred tank reactors and airlift reactors are frequently used 
for the growth of mammalian cells in suspension culture (Osman et al., 2004). 
Stirred tank reactors are mechanically agitated using an impeller to ensure a 
homogeneous environment throughout the culture and support adequate bubble 
dispersion. Baffles are used to prevent the culture medium from vortexing while
37
oxygen/air is supplied to the cells via a gas sparger at the bottom of the reactor. 
Airlift reactors are not mechanically agitated and hence generate a less shear­
intensive environment as shear forces can be detrimental to cell growth. Gas is 
sparged into part of the vessel called the riser reducing the liquid density and causing 
it to rise. Gas disengagement at the surface of the liquid leaves less dense, gas-free 
medium to re-circulate through the down-comer (Doran, 1994).
An important innovation in reactor design within the past decade has been the use of 
disposable cell culture bioreactors that rely on wave-induced agitation. These 
reactors can be operated at scales of up to 500 L and give similar growth rates and 
productivities to stirred-tank reactors (Singh, 1999). In addition, their disposable 
nature means that culture vessel preparation, usually involving cleaning and 
sterilization, is significantly simplified and can be achieved in one day rather than in 
three to four days (Tong et al., 2004).
1.2.1.5. Feeding strategies
Basic batch suspension processes in a stirred tank reactor are becoming less 
frequently used, as nutrient feeding reduces waste accumulation and nutrient 
fluctuations allowing higher cell densities and productivities to be reached (Chu & 
Robinson, 2001). The use of fed-batch processing techniques permits the 
maintenance of high cell densities at high specific productivities for prolonged 
periods of time resulting in high final product titres. A typical batch process would, 
in the past, yield around 2 x 106 cells/mL, have a production phase of around 7 days 
and have a specific productivity of around 10 pg/cell/day. Today’s extended batch
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processes can yield 10 x 106 cells/mL, maintaining cell viability over 3 weeks with a 
specific productivity of ~90 pg/cell/day (Wurm, 2004). Palivizumab (Synagis®)is an 
example of a product manufactured using a fed-batch process, in which glucose is 
fed into the reactor to replace that utilized by cells (Schenerman et a l, 1999). In 
perfusion culture systems, several reactor volumes of fresh medium can be fed into 
the culture per day while the same volume of fluid, containing product for 
purification is withdrawn from the reactor. In order to retain the cells within the 
bioreactor perfusion systems rely on cell retention mechanisms such as centrifuges, 
spin filters (Idling et a l, 2000), hollow fibre modules (Yang et a l, 2000) and 
acoustic devices (Dalm et al, 2005), thus allowing achievement of higher cell 
densities than could be obtained in fed-batch culture. The concepts of controlled 
feeding and perfusion have been combined at the 20 L scale (Yang et al, 2000). A 
controlled glucose feed was introduced to the perfusion culture giving a cell density 
of 1.8 x 107 cells/mL and an antibody concentration of 275 U/L. The high 
productivity was attributed to the high cell density and minimized product dilution 
permitted by the glucose feed (Yang et a l, 2000).
1.2.1.6. Alternatives to cell culture
Expression systems capable of producing monoclonal antibodies have been 
investigated as potentially cheaper and more efficient methods of producing large 
volumes of antibody therapeutics. In 2000, Immunex’s etanercept (Enbrel®) lost 
market share to Centocor’s infliximab (Remicade®) because Immunex was unable to 
manufacture sufficient etanercept due to a lack of manufacturing capacity and was 
forced to ration available product among patients. This episode highlighted a
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worldwide shortage of cell culture capacity. In 2001 industry analysts projected that 
demand for capacity would be four-fold greater than supply by 2005 (Molowa, 
2001). Arguably, with the construction of new manufacturing facilities cell culture 
capacity supply has now matched demand (Thiel, 2004). However, future products 
requiring large dose sizes and the imposition by health care providers of limits on 
therapeutic prices continues to stimulate research into technologies to produce 
greater quantities of antibodies at a lower cost than cell culture. Full length 
antibodies have been produced in the bacterial species Escherichia coli (Simmons et 
al., 2002). E. coli production can be easily scaled-up, is less prone to contamination 
than cell cultures, is rapid (as the organism population can double in 20 minutes, in 
comparison with mammalian cell populations that can take over 24 hours) and incurs 
lower fermentation capital costs than cell culture (Simmon et al., 2002). The 
disadvantage of this microbial system and others like it is that these prokaryotic 
organisms are incapable of performing post-translational protein gylcosylation. This 
carbohydrate component of the antibody is often necessary for the correct 
functioning of the pharmaceutical (Shields et al., 2002). However, in cases where it 
is not, such as when the antibody binds to soluble antigen, aglycosylated antibodies 
produced in bacteria could be suitable alternatives to glycosylated proteins derived 
from cell culture. Relative to E.coli, production of antibodies in fungal species such 
as Aspergillus niger or Pichia pastoris has the advantage that the protein is secreted 
by the organism into the culture medium. In contrast E. coli retains the expressed 
protein intracellularly, making recovery of the protein more complex and expensive. 
Filamentous fungal species have been shown to express homologous proteins at high 
concentrations. However, foreign proteins expressed following gene insertion are 
produced at a lower concentration and hence research has been carried out into
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increasing heterologous expression (Sotiriadis et al., 2001). Glycoproteins derived 
from fungal expression systems contain non-human carbohydrate residues which can 
be immunogenic in humans, precluding their use as therapeutic molecules. The 
glycosylation metabolic pathway of P. pastoris has been successfully genetically 
modified to yield humanized glycoforms of glycoproteins (Hamilton et al., 2003). 
The use of plant species for the production of therapeutic glycoproteins such as 
monoclonal antibodies has been considered (Joh et al., 2005). The advantages of 
production in plants include reduced capital costs, flexibility in production output 
depending on market demand and the lack of human adventitious agents in plant 
species. However, issues to be resolved before plant expressed proteins are likely to 
compete with those derived from cell culture include the long lead time to 
production, regulatory uncertainties, and concerns over plant glycosylation patterns 
in human therapeutic agents. The co-expression of human pl,4-galactosyltransferase 
and an antibody in tobacco plants has been achieved, yielding a galactosylation 
profile resembling that found in mammalian antibodies (Bakker et a l, 2001).
1.2.2. Product recovery
The purification of human therapeutic proteins derived from batch mammalian cell 
culture typically commences with the removal of cells and cellular debris. Separation 
of the cells from the cell culture medium removes intracellular contaminants such as 
host cell proteins, nucleic acids, carbohydrates and lipids. Furthermore, solid 
particulates such as cells and especially, colloidal cell debris, can foul downstream 
chromatographic steps and lead to unacceptable cross column pressure drops and a 
reduction in overall column performance.
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1.2.2.1. Centrifugation
Centrifugation is a common technique used to harvest large-scale cell culture vessels 
as it combines low running costs with uncomplicated process development and 
operational robustness (Axelsson, 1999; Hanle, 1999; Abraham et al., 2003). 
Centrifugal forces are generated and separation is achieved on the basis of the 
density difference between the heavy cell component and the lighter, liquid, 
component of the feed stream. Multi-chamber, tubular bowl and disc-stack designs 
are all available. However, the disc stack centrifuge is particularly convenient as it 
can provide intermittent solids discharge it does not require periodic disassembly and 
reassembly during the harvest to empty the bowl of solids.. The relatively low 
frequency of sediment discharge means that parallel discharge of entrained 
supernatant does not contribute strongly to product loss.
1.2.2.2. Normal flow filtration
Normal flow filtration, using depth filters, is routinely used to remove whole cells 
and cellular debris from pilot-scale cell culture broths (Charlton et al., 2000). The 
technique is also often used downstream of centrifugation operations to remove 
small particles that failed to sediment in the centrifuge. During normal flow filtration 
the direction of flow of the harvested cell culture broth is perpendicular to that of the 
filter orientation, in contrast to tangential flow filtration. The deposition of a layer of 
filtered solids on the surface of the filter presents further resistance to cells in the 
process stream and prevents them passing through the membrane. As the filter cake 
builds up increasing pressure drops are experienced across the membrane and
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eventually filtration must be stopped before the upper pressure limit of the 
equipment is reached. Positively charged filter units can be used, allowing the 
removal of particles whose size would otherwise permit their transmission through 
the filter pore. Such cationic filters also permit binding of contaminants such as 
nucleic acids, giving a more highly purified filtrate (Charlton et al., 1999).
1.2.2.3. Tangential flow filtration
Tangential flow filtration which facilitates complete retention of solids provides an 
alternative to the combined use of centrifuges and normal flow filtration or normal 
flow filtration alone for the harvesting of cell culture vessels. During tangential flow 
filtration the direction of flow of the process stream is parallel to the orientation of 
the membrane, generating sufficient shear forces to prevent the deposition of a filter 
cake. Consequently greater volumes of cell culture broth can be filtered than in 
normal flow configurations without filter blockage. Harvesting of a 1250 L cell
2 i
culture vessel at a flux rate of 27 L m ' h' , over a three hour period, by tangential 
flow filtration has been described (van Reis et al., 1991).
1.2.2.4. Expanded bed adsorption
Expanded bed adsorption provides an alternative harvesting strategy, allowing 
product capture, clarification and concentration in a single step. A bed of porous 
matrix particles, to which a product binding ligand is attached, is stably expanded in 
a column by pumping a buffer up through the bed. The flow rate is adjusted so that 
the expanded bed height is constant and the un-clarified cell culture broth is pumped
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upwards through the bed under conditions allowing product-ligand binding. Cells 
and cell debris pass through the expanded bed in the spaces between the matrix 
particles, while product in the supernatant adsorbs to the ligand attached to the 
matrix. Once clarification and adsorption have occurred the expanded bed is settled 
and the product eluted by application of a buffer favouring product dissociation from 
the ligand. By eluting the product under settled bed conditions the elution volume is 
minimized and product concentration is achieved. A study comparing two different 
expanded bed adsorption processes for the combined clarification, capture, and 
concentration of a monoclonal antibody product has been reported (Blank et al., 
2001). An expanded bed adsorption process utilizing a negatively-charged ligand, 
capable of binding a positively-charged antibody, was found to be less effective at 
clearing impurities and product aggregates than traditional clarification and 
purification steps. This problem could be overcome the use of an affinity ligand and 
a different purification scheme; however, the more expensive affinity ligand was 
susceptible to damage from the harsh cleaning solutions required for expanded bed 
adsorption systems processing crude feed preparations. This led to a loss of 
adsorption performance over repeated cycles (Blank et a l, 2001).
1.2.3. Purification
According to FDA guidance (Zoon, 1997) purification schemes for monoclonal 
antibody products for human use should prevent the introduction of contaminants 
and eliminate impurities including animal proteins and materials, DNA, endotoxins, 
other pyrogens, culture medium components, compounds that may leach from 
chromatography columns and viruses Large-scale therapeutic antibody purification
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processes usually incorporate three different chromatographic steps for contaminant 
removal and two different virus reduction steps. Virus reduction steps can usually be 
classified as virus inactivation or virus removal operations. Table 1.3 illustrates the 
purification sequences, post cell removal, employed for six marketed products.
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Herceptin Rituxin Campath™ Synagis Remicade Simulect
Affinity Chromatography 1 1 1 1 1
Virus Inactivation 2 2 2 3 2 2
Cation Exchange Chromatography 3 4 3 2 3 4
Anion Exchange Chromatography 4 3 1,5 5,6 3
Hydrophobic Interaction Chromatography 5
Size Exclusion Chromatography 4 7
Virus Clearance 5 5 4,6 4 5
Sterile Filtration 6 6 6 8 7 6
Table 1.3. Analysis of the order of unit operations employed during the purification of six different FDA-approved therapeutic monoclonal
antibodies (Sommerfeld & Strube, 2005).
1.2.3.1. Chromatography
Table 1.3 demonstrates the current reliance of the bioprocessing industry on 
chromatographic separations for product purification. Chromatography separates 
solutes based upon their differing migratory speeds through a porous packed bed of 
matrix. Selective retardation of solutes, such as product or contaminants, can be 
achieved using matrices with characteristic surface chemistries. Chromatographic 
operations can typically be segregated into a number of distinct phases. Firstly, the 
column is equilibrated with buffer to ensure provision of homogeneous, non-eluting 
conditions within the column. Then, the column is loaded with the mixture of solutes 
to be separated. Finally, the column is washed with a buffer to remove those solutes 
that are least retarded by the column. Conditions within the column are then 
commonly changed by application of an elution buffer to reduce the affinity of the 
retarded solutes for the matrix, causing them to be eluted at the column outlet. The 
elution buffer can be applied in a step-wise fashion or by the gradual increase in its 
concentration to form a gradient. Although difficult to implement especially at the 
large-scale, gradient elution allows improved solute resolution. Finally, the column 
is regenerated using different buffers to strip residual solutes and re-equilibrated in 
preparation for the next batch.
1.2.3.1.1. Affinity chromatography
Affinity chromatography is frequently used when purifying monoclonal antibodies. 
The chromatographic matrix is derivatised with a molecule which binds a solute with 
high specificity under loading conditions. Two bacterial cell wall proteins have
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evolved to promote pathogenesis when the bacteria invade the human host by 
binding the host’s defending antibodies, primarily at the Fc region. These two 
bacterial proteins, Protein A and Protein G, can be isolated and attached to the inert 
support matrix to give a matrix with high antibody specificity. A single Protein A or 
Protein G chromatographic step can yield 90% pure antibody, explaining the 
popularity of the unit operation as demonstrated in Table 1.3. The remaining 
contaminants are present due to non-specific hydrophobic or ionic interactions with 
the matrix support. These interactions interfere with selectivity and can reduce 
column capacity by blocking antibody binding sites. Recombinant forms of both 
bacterial proteins are available in which non-essential sequences are removed 
leaving only the four antibody binding sites. Two particular problems associated 
with Protein A and G matrices are (i) their considerable cost, due to complex multi- 
step production methods (ii) and the leakage of bacterial protein ligand into the 
process stream requiring subsequent chromatographic removal. Such disadvantages 
have prompted some process operators to invest in cheaper, synthetic Protein A 
adsorbents with less potential for biological contamination (Newcombe et al., 2005).
I.2.3.I.2. Ion-exchange chromatography
Ion-exchange chromatography separates contaminants from the product on the basis 
of the molecular charge of the solutes. The overall charge of macromolecules with 
multiple charged regions is determined by the pH of the solution. The pH of the 
solution at which the overall charge is neutral is called the p / of the molecule. At a 
pH lower than the p7, the molecule will have a net positive charge; the net charge is 
negative when the pH is higher than the p7. By manipulating buffer pH, successive
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solute adsorption and desorption can be achieved, thus maximizing the separation. 
Elution of bound molecules is usually instigated by increasing the concentration of 
salts on the column until they have a higher affinity for the matrix than the solute of 
interest which is out-competed for binding sites, leading to net solute desorption.
Cation exchange matrices bind positively-charged molecules as they 
themselves are negatively-charged while anion exchange matrices which have a 
positive charge bind negatively-charged species. Anion exchange steps are often 
used as a second intermediate chromatographic step, following product capture by 
affinity chromatography. Positively-charged antibody molecules flow through the 
column unhindered, while negatively-charged contaminating molecules, such as 
nucleic acids from the cells in which the antibody was expressed and endotoxins 
from contaminating bacteria, are strongly retarded. These contaminant capture steps 
maximize column capacity, yield and productivity. Cationic exchange steps can be 
used as polishing steps for the removal of leached Protein A or as an alternative to 
methods such as size exclusion chromatography for the removal of product 
aggregates, which are often constrained by operating capacity and flow rate ranges.
1.2.3.1.3. Hydrophobic interaction chromatography
Hydrophobic interaction chromatography separates solutes on the basis of surface 
hydrophobicity and can be used to separate most proteins. Hydrophobic patches on 
the surface of the molecule bind to the hydrophobic matrix when in the presence of 
salt molecules. A reduction in the salt concentration leads to solute elution; and 
hence, product elution pools have low conductivities, thereby reducing buffer 
exchange requirements during product formulation.
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1.2.3.1.4 Size exclusion chromatography
Size exclusion chromatography differs from the previously discussed
chromatographic methods in that the matrix is not derivatized with a chemical 
ligand. Separation occurs on the basis of molecular size, with the matrix pore size 
controlling the separation. Large molecules are excluded to a greater extent than 
small molecules from the bulk of the column volume and thus, migrate rapidly 
through the column, eluting first. Smaller molecules access a greater proportion of 
the column volume and take longer to elute. As the degree of separation is a strong 
function of the column length, size exclusion columns are often much longer than 
other types of columns. Unlike affinity, ion-exchange and hydrophobic interaction 
chromatography, size exclusion processes do not require the various wash and 
elution phases. However, capacity is limited and the long thin columns, packed with 
porous, compressible matrices, must be operated at low flow rates, making the 
method most useful as a final polishing step to remove product fragments and 
aggregates.
1.2.3.2 Viral removal & inactivation
The International Conference for Harmonization (ICH) identifies two potential 
sources of viral contamination: those arising from the original cell line source, such 
as the master cell bank, and those introduced during production, such as the use of 
contaminated reagents, including animal serum components (ICH, 1998). The FDA 
recommends the incorporation of at least two robust orthogonal retrovirus removal 
steps into a purification protocol. Furthermore, demonstration of the ability of the
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purification scheme to remove adventitious agents, including viruses, is required 
prior to Phase II/III clinical trials (Zoon, 1997). Viral inactivation steps are typically 
carried out using severe physico-chemical measures, such as acid, urea, detergent, 
heat or UV radiation treatment. Acid treatment is a convenient inactivation step after 
Protein A chromatography as elution is generally carried out at low pH. Methods 
such as these must be implemented with caution as they can impact negatively on 
product stability. Virus removal can be achieved using viral capture or flow-through 
chromatographic steps, the use of dead-end depth filters (20-40 nm pore size) or 
tangential-flow, ultrafiltration membranes with molecular cut-off points below 300 
kilodaltons (Sommerfeld & Strube, 2005).
1.2.3.3 Ultrafiltration
Ultrafiltration is often required during the purification of therapeutic monoclonal 
antibodies in order to exchange the product into a different chromatography buffer 
by diafiltration, to concentrate the product or, as previously mentioned, for virus 
removal. Diafiltration can be used to purify the product by removing contaminants 
below the molecular weight cut-off of the membrane which can be in the range 30 -  
500 KDa while the product is retained (Sommerfeld & Strube, 2005). The use of 
ultrafiltration as a high-resolution protein-protein fractionation method is attracting 
increasing interest as an alternative to chromatography (Filipe & Ghosh, 2005).
Formulation of the bulk purified antibody utilizes ultrafiltration to buffer exchange 
the product into the final antibody stabilizing excipient composition and concentrate 
the product prior to storage and vial filling for use. Size exclusion chromatography
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can be used for formulation; however, as this method typically leads to a dilute 
eluted product it is impractical for the monoclonal antibodies formulation making 
ultrafiltration the method of choice for most manufacturers (van Reis & Zydney, 
2001). Comparison of the two methods shows that ultrafiltration incurs lower 
material and labour costs, has a lower buffer consumption and requires less plant 
space and operating time (Kumik et a i, 1995).
1.2.4 Characterization of therapeutic monoclonal antibodies
Ensuring product quality is of paramount importance when manufacturing any 
therapeutic agent. Complete physicochemical analysis of small molecule 
pharmaceuticals is a viable option due to their relatively simple structures, allowing 
product consistency to be monitored. In this manner, production batches of product 
can be easily compared with product used and proven to be safe in clinical trials.
Until recently, the complexity of biopharmaceuticals such as recombinant 
proteins, including monoclonal antibodies has meant that a complete 
physicochemical analysis of the product was not considered possible. Safety and 
efficacy were ensured by adopting the attitude that ‘the manufacturing process 
defines the product’. In practice this meant that even minor changes to the 
manufacturing process could necessitate clinical studies to prove that no product 
change had occurred. Process scale-up required considerable process understanding 
and the manufacturer had to demonstrate rigorous process control within self- 
imposed limits.
Subsequent advances in analytical technology have changed the attitude of 
regulators to the extent that for a ‘well-characterized biological’ the process may no
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longer define the product. Although this would seem to represent a significant 
change in regulatory policy, in order to ensure product safety manufacturers will 
need to (i) consider whether current analytical techniques adequately cover 
characteristics affecting function and potency and (ii) what degree of molecular 
structural change is permissible in a given product. This latter consideration would 
require a full understanding of the complex relationship between antibody structure 
and therapeutic function (Chirino & Mire-Sluis, 2004).
1.2.4.1. Sources of antibody heterogeneity
Antibody heterogeneity can occur due to variations in either carbohydrate side- 
chains or in the protein backbone. Carbohydrate side-chains are linked to a 
conserved asparagine residue in the CH2 region of the antibody. Figure 1.3 shows 
the typical structure of these oligosaccharide side-chains. This type of heterogeneity 
can arise due to changes in the manufacturing process eg. the fermentation 
conditions (Schmelzer & Miller, 2002). As the carbohydrate side-chains are an 
integral part of the Fc structure, variation in the side chains causes Fc structural 
heterogeneity which may, in turn, affect ivrecepter interactions (Krapp et al., 2003).
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Fucose
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Figure 1.3. Schematic of IgG glycoforms. The core structure {GalO + Fucose) is
' j Q n
normally composed of Asn -Nfi2-GlcNAc(fucose)-GlcNAc-mannose-(mannose- 
G1cN A c)2, where GlcNAc is A-acetylglucosamine. Variation among individual 
glycoforms includes attachment of one {Gall + Fucose) or two {Gal2 + Fucose) 
terminal galactose units, attachment of sialic acid to the terminal galactose, and/or 
attachment o f a third GlcNAc arm (bisecting GlcNAc). Reproduced from Shields et 
al., 2002.
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Terminal galactose levels correlate with complement-mediated cell killing in vitro 
(Tsuchiya et a l,  1989) while increased levels of core fucosylation decrease 
antibody-dependent cellular cytotoxicity (Shields et al., 2002). Studies have 
suggested that antibody-dependent cellular cytotoxicity has a significant effect on the 
in vivo efficacy of cancer therapeutic antibodies such as trastuzumab and rituximab 
(Clynes et a l, 2000; Cartron et al., 2002). Not only are the carbohydrate side chains 
important for the biological function of the glycoprotein but they have also been 
shown to impact on both enzymatic and thermal degradation (Bernard et al., 1982; 
Runkel et al., 1998) and on product solubility (Stowers et al., 2002) with 
implications for product formulation and storage.
Protein backbone variations can be variously attributed to the cyclization of 
N-terminal glutamine residues to pyroglutamate, the partial enzymatic cleavage of 
C-terminal lysine residues by carboxypeptidases and unpaired cysteine residues. 
Degradative modifications, such as asparagine deamidation, aspartate isomerization 
and oxidation of methionine residues, can also be responsible for antibody 
heterogeneity (Harris et al., 2004).
Shelf lives of 1.5-2 years are typically required in order to manage 
inventories of product. Product-degrading hydrolysis reactions that occur in liquid 
formulations of monoclonal antibody therapeutics can lead to undesirable protein 
heterogeneity and dose-to-dose variation. For example, isoaspartate formation of the 
aspartate 102 residue on trastuzumab (Herceptin) leads to a decrease in antigen- 
binding affinity (Chirino & Mire-Sluis, 2004). Pre-formulation studies are designed 
to help the developer of the therapeutic to determine solution conditions such as 
ionic strength and pH to minimize degradation which may affect drug efficacy and 
safety and to ensure product consistency. Several degradation routes may need to be
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controlled to develop a marketable liquid formulation and the selected conditions 
may be sub-optimal for the control of any given degradation process (Kroon et al., 
1992).
Solid dosage forms, such as lyophilized protein, significantly reduce product 
degradation because the removal of water retards many degradative hydrolytic 
reactions such as aspartic acid residue isomerization (Harris et al., 2004). During the 
lyophilization process the protein is frozen and dried by sublimation which subjects 
the protein to stresses that are typically controlled by the addition of excipients such 
as sugars. Such exipients control product aggregation which is the major degradative 
process for lyophilized proteins (Cleland et al., 2001).
1.2.4.2. Analytical tests to assess heterogeneity
An extensive range of analytical techniques have become available for assessing the 
structure of protein therapeutics (Table 1.4). Mass spectroscopy in particular has 
become a valuable tool for detecting subtle changes in protein structure. Cell-based 
functional bioassays can be used to assess lot-to-lot comparability and have been 
used to detect differences between products not identified by physicochemical tests 
(Chirino & Mire-Sluis, 2004). Pharmacokinetic and pharmacodynamic studies in 
animal models are used to characterize bioavailability, clearance mechanisms and 
efficacy. Animal testing can provide structural/functional data allowing 
physicochemical product analysis to be of more use in comparability studies 
(Chirino & Mire-Sluis, 2004).
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Form of 
Heterogeneity
Possible influencing 
factors
Analytical test
Amino acid 
sequence
• Amino acid 
substitution
• Deamidation
• Oxidation
• Fermentation and 
purification process 
changes.
• Cell line stability
• Formulation
• Sample handling
• Trypsin peptide mapping/mass 
spectrometry
• Capillary electrophoresis
• IEF
• Ion-exchange-HPLC
• Circular dichroism
Aggregation • Formulation
• High product 
concentrations
• Sampling handling
• Analytical ultracentrifugation
• Light scattering
• Size-exclusion HPLC
Glycosylation • Changes in 
fermentation process
• Capillary electrophoresis
• Liquid chromatography/mass 
spectrometry
• Electrospray ionization mass 
spectroscopy
• Matrix-assisted laser 
desorption-time of flight mass 
spectroscopy
Truncation
/fragmentation
• Fermentation changes
• Manufacturing 
changes leading to 
protease/ peptidase 
contamination/ 
activation
• Sample handling
• Mass spectroscopy
• Size-exclusion chromatography
• SDS-PAGE
• IEF
• Size exclusion HPLC
Disulphide
rearrangement
• Fermentation changes
• Sample handling
• Trypsin-peptide mapping 
/ hydrophobic interaction
Table 1.4. Useful analytical tests to assess protein heterogeneity (adapted from 
Chirino & Mire-Sluis, 2004)
57
1.2.4.3. Controlling product quality
Regulatory authorities controlling the marketing of therapeutics demand 
manufacturing processes capable of repeatedly and reliably producing a finished 
product of a specified quality. Process validation is the act of demonstrating and 
documenting that a manufacturing process meets the requirements and covers all 
elements of a manufacturing process, from development through to final validation 
at the production scale.
The chosen manufacturing method must be defined, justified (based on 
consideration of the physical and chemical properties of the molecule) and then fully 
described. Data generated at different scales of operation throughout the 
development of the manufacturing process must verify the validity of the process 
employed. Laboratory-scale batches, at the research and early development stages, 
focus on the definition of critical product performance characteristics, thus facilitate 
the choice of the appropriate manufacturing process. Pilot-scale batches are used in 
the process development and optimization stages and should correspond to at least 
10% of the future industrial-scale batch. The role of pilot batches is to ensure the 
smooth transition to the industrial scale product through development of a robust and 
reproducible manufacturing process. Pilot batches challenge the method proposed for 
routine production by identifying and evaluating the potential difficulties in and 
critical points of the manufacturing process; they also permit specification of 
apparatus and methods most appropriate to large-scale production. In this way pilot- 
scale batches provide a high level of assurance that the process will be feasible on an 
industrial scale without loss of product quality. Typically, full data for three
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consecutive production-scale batches are required prior to the commencement of 
product marketing.
Proposed changes in the production process are controlled by clearly defined 
procedures. Data to demonstrate that the revised process will result in a product of 
the desired quality are required. Minor changes, which can be shown not to impact 
the quality of the product, are unlikely to require regulatory approval, however, 
significant changes to processes are typically subject to regulatory scrutiny and 
appropriate supporting data must be submitted by way of a variation to the marketing 
authorization.
1.3. Challenges of process specification
1.3.1 Centrifuge specification
Different approaches to the scale-down of industrial centrifuges have been adopted 
(Leung, 1998). Early attempts to address scale-down were based on reducing the 
capacity of the smallest scale disc stack centrifuges. For example, the separation 
capacity of a disc stack centrifuge has been reduced 10-fold by blanking off the 
majority of the separation discs and by carefully locating the remaining active discs 
within the stack in a position which best mimics overall centrifuge performance 
(Mannweiler & Hoare, 1992). In this fashion, a ten-fold reduction in the flow rate 
required to characterize centrifuge performance was achieved; this approach was 
successfully demonstrated for materials both sensitive and insensitive to shear effects 
in the feed zone. However, large feed volumes are still required to fill the centrifuge 
bowl. A series of interlocking inserts has been used to reduce the separation area by
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76%, while also giving a 70% reduction in bowl volume, thereby reducing to 30% 
the volume and flow rate of process material required for characterization of the 
centrifuge recovery stage (Maybury et al., 1998). Methods for using a bench-top 
centrifuge in order to mimic the recovery performance of industrial-scale centrifuges 
have also been described. For example, the recovery of polyvinyl acetate particles 
was well predicted by the bench-top centrifuge method; this was in contrast to the 
results for protein precipitates, where break-up of solids was found to reduce 
separator capacity 10-fold (Maybury et al., 2000). A laboratory centrifuge was also 
used to mimic the recovery and dewatering performance of a multichamber-bowl 
centrifuge using a protein precipitate feed stream. Precipitate break-up in the 
continuous-flow centrifuge led to a reduction of approximately 50% in clarification 
performance (Boychyn et al., 2001).
Computational fluid dynamics (CFD) has shown that significant energy 
dissipation occurs in the feed zone of tubular bowl (Jain et al., 2005), multichamber- 
bowl, disc stack and CARR Powerfuge™ centrifuges (Boychyn et al, 2003). 
Maximum energy dissipation rates of 6 x 105 W kg 1 and 12 x 105 W kg'1 have been 
determined for a multichamber-bowl centrifuge, under flooded and non-flooded feed 
zone conditions, respectively. Both calculations were performed assuming a feed 
volumetric flow rate of 22 L hr'1 and a centrifuge bowl rotational speed of 167 rps. 
Similarly, a maximum value of 2 x 105 W kg'1 was determined for the disk stack 
centrifuge, operated at between 15 and 80 L hr'1 and at 165 rps; the maximum energy 
dissipation rate occurring in the feed zone of the CARR Powerfuge™ was calculated 
to be 14 x 105 W kg'1, at a flow rate of 20 L hr'1 and a bowl rotational speed of 255 
rps (Boychyn et al., 2004). A small, high-speed, rotating-disc device, designed to 
reproduce these energy dissipation rates in the centrifuge feed zone has been used to
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shear milliliter quantities of process material prior to centrifugation in a laboratory 
test-tube centrifuge (Boychyn et al., 2001. For shear sensitive materials, this shear 
treatment facilitated more accurate predictions of production-scale equipment than 
the use of the laboratory centrifuge alone (Boychyn et al., 2001).
When developing a centrifugation process the objective is to achieve the 
target degree of clarification while maintaining high flow rates. To achieve this 
objective development scientists in pilot plants aim to predict the performance of the 
industrial-scale centrifuge, over an appropriate flow rate range, using the equivalent 
settling area or sigma theory for centrifuge scale-up. Sigma theory (Ambler 1959) is 
based on Stokes’ law and can be used to describe the clarification process in a disc 
stack centrifuge. The settling velocity (vc(r)) of a small, spherical particle in a 
laminar flow field is given by:
where d  is the particle diameter, Ap  is the density difference between the particle and 
the suspension, p is the dynamic viscosity of the suspension, ca is the angular bowl 
velocity, r is the settling radius and vg is the settling velocity of the particle under 
gravity. It is assumed that settling is unhindered and that laminar conditions apply, 
i.e. Re(=vc(r)pd/p) <0.5  where p  is the liquid phase density.
The definition of the separation area, I ,  for the recovery of 100% of particles is 
(Ambler 1959):
where V is the volume of material processed in time, t, for a batch centrifuge; Q is 
the flow rate for a continuous flow centrifuge.
2 x  26) r = — co r 
g
Equation 1.1
Equation 1.2
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Applying Stokes’ law to a bottle centrifuge with swing-out rotor and 
integrating Equation 1.1 across the settling radius yields (Maybury et al., 2000):
where t is the time during which the particle is being sedimented and Rj and R2 are 
the inner and outer radii, ie. the distances between the centre of rotation and the top 
of the liquid and the bottom of the tube, respectively. The group vgt indicates the 
equivalent distance settled in a gravity settling tank.
Rearranging and substituting Equation 1.2 into Equation 1.3 gives,
The acceleration and deceleration phases of a centrifugation run can contribute 
significantly to settling when the spin time is short. If it is assumed that the rate of 
change in rotational speed is constant in each phase the following modified formula 
can be used (Maybury et. al. 2000):
where, jc and y  are the fractional times required for acceleration and deceleration 
respectively.
In a disc stack centrifuge sedimentation of particles occurs in the channels 
between discs. Process suspension enters the separation channels at the outer radius 
and flows through the channels towards the centre of the disc stack. If a single 
channel is considered, a particle is considered to be separated when it reaches the 
upper boundary of the disc space. For a particle of gravity settling velocity, vg,
Equation 1.3
Equation 1.4
V ^ 2( 3 - 2 x - 2 y )
/ \ Equation 1.5
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following the most unfavorable particle trajectory, the hydrodynamic throughput 
capacity, Q, at which the particle will just be separated is given by considering the 
resultant particle motion, due to both hydrodynamic flow through the discs and to 
settling under the action of centrifugal force. Assuming the particle moves with the 
fluid, the velocity of the particle, u(h), through the gap between the discs is given by,
dO * /' z
u{h) = --------— Equation 1.6
dh .ln  r
where Q* is the limiting hydraulic throughput capacity for which the particles are
just recovered, z is the number of discs and dQVz is the flow rate through an area
dh.ln  r\ r is the radius at any point during flow through the discs and h is the gap
width between the discs. The particle velocity opposing this fluid flow is given by
vc(r)sinO where vc(r) is defined in Equation 1.1; the particle velocity carrying the
particles to the upper boundary of the disc space is vc(r)cos6 where 6 is the half-disc
angle. The resultant particle trajectory with radius, r, is given by,
dr w(/z)tan<9 c  . _—  = ---- -------- Equation 1.7
dh vc(r)
Integration over the length of the disc gives the expression for the limiting hydraulic 
throughput capacity of the disc stack centrifuge (Mannweiler & Hoare, 1992):
2
Q* = — nzco2 cot 6{r\ -  r,3 )vg = vg Equation 1.8
where r2 and r} are the outer and inner disc radii, respectively and Eds is the so-called 
equivalent settling area of the disc stack centrifuge. The full derivation of the 
relationship, which is outside the scope of this thesis, is given by Mannweiler & 
Hoare (1992) and elsewhere.
By maintaining the ratio of flow rate to separation area, equivalent 
clarification efficiencies should be achieved between the development and industrial
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scale centrifuges (Ambler, 1959). Sigma theory can be used to allow industrial scale 
equipment performance to be predicted using centrifuges of different sizes, 
geometries and modes of operation. Furthermore, a batch laboratory-scale centrifuge 
can be used to predict the clarification performance of a continuous, industrial disc- 
stack centrifuge, at different flow rates:
Q d s  _  K a b  Equation 1.9
c  y  t c yds ds 1 l a b ^  la b ^  lab
where Qds is flow rate through the disc-stack machine, Ids and I iab are equivalent 
separating areas for the disk stack centrifuge and laboratory centrifuge, respectively, 
tiab is the residence time in the laboratory centrifuge, Viab is the volume of material in 
the centrifuge tube and Q* and Ciab are calibration factors to account for non-ideal 
flow conditions and are assumed to be independent of factors determining 
sedimentation performance. C\ab is considered as the reference case and, hence, is 
equal to 1. The correction factor for disc stack centrifuge, C&, is in the range 0.4 -  
0.5 (Pinheiro & Cabral, 1993). is a compound group covering many aspects of 
centrifuge design. Values are based on actual system performance, primary under 
industrial conditions. For design purposes, a fixed value for Cds is typically assumed; 
it must be understood that deviations from predicted performance of the order of ± 
20% can be attributed to variations in Cds (UCL pilot study experience).
1.3.2 Normal flow filter specification
Normal flow filters can be operated in two different modes. During constant-pressure 
filtration the pressure drop across the filter is maintained, leading to a reduction in
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the filtration rate over time, as the build-up of a cake of filtered material increases 
resistance to flow. Alternatively, during constant-rate filtration, the flow rate is 
maintained by gradually increasing the cross-filter pressure drop. O f the two modes 
of operation, constant-rate filtration is more common. Scaling-up of filtration area 
from the pilot plant to manufacturing-scale is traditionally based upon maintaining 
an equivalent applied pressure profile, filter medium and ratio of filtrate volume to 
surface area. Filtration process development in the pilot plant involves identifying 
flow rates that allow the required level of productivity without causing excessive 
cross-filter pressure drops which could damage the filter and lead to equipment 
failure. Operating at high cross filter pressure drops maximizes productivity; 
however, it can lead to filter clogging as filtered solids can be driven into the filter 
pores and biological filter cakes are highly compressible.
Laboratory-scale filtration equipment is often used to select filter media, 
filter aids and pre-coats. Laboratory filters are often operated in batch mode, have 
simple geometries and utilize compressed air as the driving force for filtration. 
Constant pressure tests using such equipment can provide information about filtrate 
flux rates and filter cake dewatering at different pressures. Further, cake resistance 
and compressibility values can be determined from these experiments, allowing 
identification of a pressure profile which supports maintenance of a constant, 
specified filtration flux rate. However, such laboratory-scale equipment often poorly 
predicts large-scale filter performance, because they are operated in batch, rather 
than continuous mode, and because they are geometrically different. Superior 
predictions of the flux profile for a pilot filter have been achieved by modifying a 
traditional laboratory-scale Nutsche filter so that it could be operated semi- 
continuously and in a horizontal, rotating configuration, ensuring that the critical
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parameter of filter cake structure resembled, as closely as possible, that of the large- 
scale system (Reynolds et al., 2003). Automated, high-throughput evaluation of feed 
streams has been achieved using a custom-designed 8-24-well filter plate with a 
membrane area of 0.8 cm2 per well (Jackson et al., 2005). Different membrane types 
could be evaluated simultaneously and specific cake resistances determined for 
different feed suspensions.
1.3.3 Tangential flow filter specification
Tangential flow filtration has traditionally been scaled-up and -down by maintaining 
the filtrate volume-to-membrane surface area ratio. Membrane material, pore size 
and channel heights are also held constant while the number of channels is increased 
in order to provide additional membrane area. Development of tangential flow 
filtration processes involves the identification of the minimum trans-membrane 
pressure capable of achieving high permeate flux rates. Excessive trans-membrane 
pressures can lead to severe membrane fouling and reduced filter life-times. 
Increasing the linear velocity of the process fluid through the membrane channel 
increases the level of shear, thus reducing the protein gel-layer at the membrane wall 
and increasing flux rates. However, excessive shear rates can be damaging to protein 
products during ultrafiltration or to cells being removed by microfiltration and 
should be applied with caution.
Commercially available, small-scale tangential flow filters typically have 
shorter channel lengths than large-scale filters (Brose et al., 1996); however, failure 
to maintain channel lengths can significantly impact on process parameters. The 
pressure drop between the filter inlet and outlet is a function of the channel length
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and, in turn, determines the trans-membrane pressure drop which drives transport 
across the filter. Linear scaling of microporous membrane filtration systems, by 
maintaining constant channel length, has been described (van Reis et a l, 1991). 
Scaling of ultrafiltration membrane processes, by maintaining fluid dynamic 
parameters such as protein concentration at the membrane wall has also been 
achieved (van Reis et al, 1997).
1.3.4 Chromatography process specifications
Scaling of chromatography columns is traditionally carried out by maintaining the 
process fluid linear velocity and the matrix bed height. If these two parameters are 
held constant, the residence time of fluid through the column will also be 
maintained. Scaling-up and-down is achieved by varying the column diameter. 
Process development involves identifying matrices and buffer conditions to 
maximize column capacity and yield. ‘Scouting’ experiments, using columns with 
reduced bed heights, have been used to select the most promising matrices and 
conditions and have the advantage of requiring significantly smaller volumes of feed 
material (Fahmer et a l, 1999). Predictions of large-scale column binding capacities 
and elution profiles, however, are typically determined at the large-scale bed height 
and operating linear flow rate. Shorter bed height columns typically have higher 
capacities per unit volume of matrix, as the concentration gradient between the bulk 
flow and the matrix is high at the entrance to the column. Further down in long bed 
height columns this gradient is reduced as bulk phase protein has bound higher up 
the column. The use of general rate models could aid the extrapolation of data from
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columns with reduced bed heights to the large-scale, but are yet to be widely used in 
industry (Gu et al., 1993).
Such models typically aim to predict phenomena occurring on the column 
itself; however, when using small columns with reduced bed heights, dispersion 
occuring in connecting tubing, dead volumes and detectors tends to predominate 
over column effects. In a study using a 1 mL chromatography column, the extra­
column volume made up over 22 % of the total volume and extra-column broadening 
constituted over 60 % of the total broadening in the system (Kaltenbrunner et al., 
1997).
A further difficulty in the linear scale-up and -down of chromatography 
columns is that many commercially-available resins are highly porous to aid solute 
mass transfer kinetics; however, this also renders the material prone to compression 
and deformation. Obtaining heterogeneous matrix packing densities throughout 
columns is challenging (Shallikar et al., 2003) and difficult to reproduce at varying 
scales. Narrow, laboratory-scale columns typically have less well-compressed beds, 
as the column wall supports the matrix. In wide diameter columns, increased levels 
of bed compression lead to increased cross-column pressure drops, which can 
prevent large-scale columns from being operated at the same linear flow rates as 
laboratory scale-columns. Models have been developed to predict the increased 
pressure drops and maximum operating flow rates of large-scale columns; however, 
the impact on performance characteristics such as column capacity and yield is less 
well understood (Shekel & Fotopoulos, 2001).
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Chapter 2 -  The use of ultra scale-down centrifugation for the prediction of 
normal and soft feed, industrial-scale, disc stack centrifuges, used for the 
clarification of mammalian cell culture broth at pilot scale.
2.1. Introduction
The development of primary recovery process for monoclonal antibody 
manufacturing processes occurs in the pilot plant. Typically, a flow rate excursion 
experiment is carried out in which a cell culture vessel is harvested at different flow 
rates through a pilot centrifuge and the degree of clarification achieved determined 
for each flow rate. Upper and lower flow rate limits for achievement of the target 
degree of clarification within a sensible time frame are determined. These limits are 
converted into upper and lower manufacturing flow rates by maintaining the flow 
rate-to-equivalent settling area ratio, according to sigma theory (Section 1.3.1). Such 
an experiment can require the generation of 500 L of cell culture broth and hence are 
frequently run only once, to minimize development costs. The consequence of 
having such a small body of data is that processes are frequently not fully optimized; 
the effects of harvesting at different time points during the fermentation are not fully 
understood. Thus centrifuge development is based on the ‘worst-case scenario’ in 
which harvesting occurs at the very latest time point, when cell viability is low, 
making cell separation the most difficult. The clarifying filter area, downstream of 
the centrifuge, is often oversized in order to avoid excessive cross filter pressures 
and associated equipment failure. Such contingency allowances add to product costs 
and dimishes the ability of the sponsor to recoup the cost of bringing the product to 
market.
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Alternative techniques to centrifuge process development, making use of 
laboratory systems requiring significantly smaller volumes of process material, have 
been proposed (Section 1.3.1). Such methods offer not only the potential for 
improved process optimization but also allow process development studies to be 
undertaken earlier in the product lifecycle, thus reducing the ‘time to market’.
This chapter describes the development of an ultra scale-down centrifugation 
technique for use with mammalian cell suspensions and its verification using two 
centrifuges operated, in the Lonza pilot plant, but equivalent in scale to systems used 
in the clarification of broth from 2000 L bioreactors in the manufacturing facility. 
One of the large-scale centrifuges had a standard design feed configuration; the other 
had a hermetic feed configuration. The use of hermetic feeds ensures feed-zone 
flooding and allows the energy dissipated as a result of process fluid acceleration 
towards the centrifuge rotational speed to occur in a greater fluid volume, thus 
reducing potential damage to fragile solids.
The use of the data generated by the ultra scale-down centrifuge technique 
for the development of a ‘windows of operation’ visualization tool is described. The 
window of operation method of presenting data allows process development 
engineers to rapidly identify operating conditions that will allow specified processing 
performance criteria to be met.
Finally, a product analysis study is included, to demonstrate product 
comparability between the large-scale and the ultra scale-down centrifuges. The 
study seeks to confirm that the equipment and processes used during the ultra scale- 
down technique do not negatively on impact product quality; thus, supernatant from 
the scale-down centrifuge can be used for development of subsequent downstream 
operations.
70
2.2. Materials and Methods
2.2.1. Experimental Overview
A sample of large-scale cell culture broth, collected at harvest point, was subjected 
to hydrodynamic forces in a rotating disc device in order to study shear 
susceptibility. The sheared cell suspension was subsequently transferred to a bench- 
top centrifuge in order to mimic the sedimentation occurring in the industrial scale 
equipment, at different flow rates, according to Equation 1.9. Broth clarification was 
studied at industrial scale, using disc stack centrifuges with standard and hermetic 
feed configurations.
2.2.2. Cell culture broth
Experiments were undertaken using cell culture broth, containing the GS-NSO 
myeloma 6A1( 100)3 expressing a chimeric B72.3 IgG4 antibody, raised against 
tissue from a metastatic breast carcinoma and recognizing a large tumour-associated 
glycoprotein termed TAG-72 (Johnson et al., 1986). The broth was produced using a 
500 L fed-batch, stirred-tank fermenter and protein-free media (Osman et al., 2004). 
All studies were undertaken using broth from the late decline phase of growth when 
cell viability was below 10% and the concentration of solids was 1.5% v/v. An 
example of a growth profile and the harvest point is given in Figure 2.1
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Figure 2.1. -  Growth profile of cell culture material used in centrifugation experiments 
showing harvest point. The broth was produced using a 500 L fed-batch, stirred-tank 
fermenter and protein-free media. The cell line was the GS-NSO myeloma 
6A1( 100)3 expressing a chimeric B72.3 antibody. Figure shows antibody titre (■)
total cell count ( • )  and cell viability (  A).
72
2.23. Centrifuge equipment
Laboratory scale: Either a Beckman J2-MI laboratory centrifuge, fitted with the JS-
13.1 swing-out rotor (Beckman Instruments (UK) Ltd, High Wycombe, UK) or an 
IEC Centra CL3 laboratory centrifuge, fitted with the ‘243’ swing-out rotor (IEC 
International Equipment Company, Massachusetts, USA) was used to clarify cell 
suspension samples.
Industrial scale: Continuous-flow Alfa Laval BTPX 205 or Alfa Laval BTPX 305H 
disc stack centrifuges (Alfa Laval, Lund, Sweden) were used to process cell culture 
broths. The BTPX 205 is designed specifically for cell harvesting, broth clarification 
and cell debris separation at the pilot scale, is steam sterilizable and has cleaning-in- 
place capability (CIP). The BTPX 305H has many of the same features but is 
hermetically sealed and bottom-fed via a rotating feed line, in order to more gently 
accelerate the process stream to the speed of the bowl and to ensure the exclusion of 
air from the feed zone .
2.2.4. Centrifuge protocol
Laboratory scale: Oak Ridge Polycarbonate centrifuge tubes, 50 mL, filled with 40 
mL of cell culture broth were used with the Beckman J2-M1 laboratory centrifuge. 
Polypropylene centrifuge tubes, 15 mL, filled with 10 mL of broth were used with 
the IEC Centra CL3 laboratory centrifuge. Following each centrifuge run the 
uppermost 15 mL or 5 mL of supernatant, respectively, was removed by pipette, 
taking care not to disrupt the sediment at the bottom of the tube. Samples were spun
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for between 20 and 46 minutes at 4000 rpm in order to give V/tZ ratios of between
1.04 and 2.42 x 10'8 m s '1.
Industrial scale: The mammalian cell culture broth was harvested using either an 
Alfa Laval BTPX205 or an Alfa Laval BTPX305H continuous disc stack centrifuge 
by over-pressurizing the vessel with compressed air. Flow rates were varied between 
170 and 600 L hr'1.
2.2.5. Rotating disc device
The rotating disc device consisted of a stainless steel chamber of diameter 50 mm 
and height 10 mm. The rotating elements were fabricated from a smooth aluminum 
alloy, coated with a thin layer of PTFE, mounted on a stainless steel shaft. The 
rotating disc had a diameter of 40 mm and a depth of 1 mm. The shaft of the element 
was extended through a PTFE bearing and was connected to a high speed DC motor 
powered from the mains, via a transformer. The transformer provided a range of 
speeds from 0 to 20,000 rpm measured using an optical probe.
The top and bottom of the stainless steel chamber are equipped with entrance 
and exit ports with fittings to allow the attachment of syringe fillers. The device was 
filled from the bottom allowing trapped air to escape though the top. Once the 
chamber was full, inlets and outlets were sealed prior to operation of the device. The 
assembly was mounted on a heavy metal base to reduce vibration during 
experiments.
Previous computational fluid dynamic analysis has allowed maximum 
dissipation rates to be determined for a variety of centrifuges with different feed-
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zone configurations (Figure 2.2). Details of how the flow fields have been mapped 
have been provided elsewhere (Boychyn et al., 2001). From this information and a 
similar analysis of maximum energy dissipation rates within the rotating-disc device 
at different rotating-disc speeds, the rotating-disc device can be operated at speeds 
that will subject shear-sensitive process material within the device to similar levels 
of energy dissipation as it would experience in the feed-zone of the centrifuge.
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(a) Cross section 
of a disc-stack 
centrifuge
(b) Cross section 
of a quarter of 
the rotating-disc 
device
Shaft
Rotating disc
Figure 2.2. Computation Fluid Dynamic (CFD) analysis o f the (a) feed zone of a 
disc-stack centrifuge and (b) the rotating disc device. The different colours represent 
different energy dissipations and together the analyses show that energy dissipation 
rates in the rotating-disc device can be generated which are comparable to those in 
the feed zone of the centrifuge (Boychyn et al., 2001).
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2.6.6. Analysis
2.2.6.1. Particle size distribution data: A particle size analyzer (Mastersizer, 
Malvern Instruments, Southborough, MA) was used to determine the size 
distribution of the cell debris from a 5 mL sample of cell culture broth. 
Measurements were taken in triplicate.
2.2.6.2. Determination o f  antibody concentration: Antibody concentration was 
determined using a protein A affinity column and a HPLC system consisting of a 
pump, an autosampler and an UV-detector. Effluent was monitored at 280nm. 
Solvents containing 50mM glycine and 150mM sodium chloride were employed. 
The pH of solvent A was adjusted to 8.0 and the pH of solvent B was adjusted to 2.5. 
The column was equilibrated using 100% solvent A at a flow rate of 2 mL.min1. 
After 200 pL of sample was injected, a 1-minute linear gradient to 100% solvent B 
was run and held at that point for a further 35 minutes before returning to the 
equilibration conditions. Replicates of test samples were within ±5% of their mean. 
Inter-assay controls were within ±10% of their set values.
2.2.6.3. Protein assay. The soluble protein concentration of feed and supernatant 
streams was measured by the method of Coomassie (Bradford, 1976). The assay uses 
Coomassie brilliant blue (G250), which when in protonated form, is pale orange/red 
in colour. Proteins bind strongly to the dye forming both ionic and hydrophobic 
interactions that suppress protonation and result in a colour change to blue. A 
calibration curve was generated from standards of bovine serum albumin (BSA), 0- 
1500 pg/ml. The response was linear at protein concentrations between 0 -  1500 
pg/mL (Figure 2.3). Samples were diluted into this range, using PBS. Diluted sample
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was added to neat reagent in the volumetric ratio of 1:30 and the shift in optical 
density was monitored by a spectrophotometer, at 595 nm, after 5 minutes.
2.2.6.4. DNA assays: DNA quantification was carried out using a 2100 Bioanalyser 
(Agilent Technologies, Palo Alto, CA) system and a DNA 12000bp assay kit 
(Agilent Technologies, Palo Alto, CA). The bioanalyser sizes and quantifies the 
DNA in 12 samples simultaneously within the confines of a disposable microchip by 
comparison with a kit-supplied molecular weight ladder run on the same microchip. 
The microchip consists of a series of interconnecting micro-channels fabricated, in 
the glass, which are filled with a gel-dye matrix. DNA fragments are separated 
according to their size by means of molecular sieving in the gel matrix and are 
detected by laser-induced fluorescence. Associated software can quantify the DNA 
in a sample on the basis of the area below the peaks on the sample electropherogram.
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Figure 2.3. Standard curve used for determining protein concentrations by the 
Coomassie method. Data points are the means for three replicate measurement and 
error bars are standard deviation.
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The microchips were prepared as recommended by the manufacturer, with minor 
modifications, using crude supernatant samples. 400 pi of DNA gel matrix was 
mixed with 20 pi of DNA dye concentrate and spin filtered at 3000 rpm for 10 
minutes. The gel-dye mix was then loaded onto a new DNA chip. During this time 
the gel-dye mix was protected from the light. 5 pi of DNA marker was added to the 
ladder well and all sample wells, lp l of sample was added to each of the sample 
wells and 1 pi of DNA ladder was added to the ladder well. The DNA sample chip 
was vortexed for 60 s before being inserted into the receptacle; the run commenced 
within 300 s of vortexing. The electropherograms of the ladder well and samples 
were checked to ensure all peaks were present and well-resolved, that the ladder 
baseline was flat and that marker readings were over 20 fluorescence units higher 
than baseline readings.
2.2.6.5 Percentage solids remaining in supernatant: Centrifuge performance was 
evaluated in terms of the percentage solids remaining in the supernatant, S, as 
follows:
S(%) =
r O D ,-O D ^  
OD , -  OD0 j
xl00 Equation 2.1
where all OD values are measured at 550 nm wavelength; ODa refers to the 
supernatant obtained after extended centrifugation (V = 5 mL, t = 5520 s, N = 66.7 
rps, IEC centrifuge, giving V/t.E = 5.2 x 10'9 ms'1); ODs refers to the supernatant 
obtained in the centrifugation test procedure; ODf to the feed stream prior to 
centrifugation.
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2.2.6.6 Antibody comparability study: 40 mL samples of clarified cell culture broth 
and supernatant from the ultra scale-down centrifuge and industrial centrifuge were 
purified using 20mL disposable columns packed with rmp Protein A Sepharose FF 
matrix (Amersham Bioscience, Uppsala Sweden). The columns were packed and 
operated under gravity. Antibody-containing fractions were pooled and dialysed 
against phosphate-buffered saline before being concentrated using a spin 
ultrafiltration unit (Millipore, Billerica, MA).
Sample product integrity was analyzed using the 2100 Bioanalyzer (Lab on a 
chip) and a Protein 200 Plus Assay Kit (Agilent Technologies, Palo Alto, CA). The 
protein chip uses the same microfluidics technology as the DNA chip previously 
described (Section 2.2.6.4.). 4 pL of sample was added to 2 pL of sample buffer in 
the presence and absence of the reducing agent P-Mecaptoethanol and heated in 
boiling water for 60 s. Once the sample had cooled it was spun at 13,000 rpm for 15 
s and the sample diluted with 84 pL of distilled water. 6 pL of diluted sample was 
applied to the protein chip wells, where proteins are separated by size via acrylamide 
sieving. The protein chip was loaded into the 2100 Bioanalyzer where, following the 
separation process, each protein was induced by fluorescent excitation at 633 nm.
10 pg samples of purified antibody were used to evaluate the protein pi; these 
were loaded onto an Isogel Precast Agarose IEF plate with pH range 3 - 1 0  
(Cambrex, East Rutherford, NJ) and run according to the manufacturer’s instructions 
with minor modifications. Isoelectric focusing standards with pis between 3.5 and
9.5 (Pharmacia LKB, Piscataway, NJ) were run in order to determine the pi of 
product bands. The gel was developed using Coomassie Brilliant Blue R250 stain 
and the appropriate destaining solution and accepted on the criteria that all pi 
markers were clearly focused and in the expected pattern and pi range.
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The presence of aggregates and antibody fragments was determined using a 
Zorbax Bioseries GF 250 column (9.4mm ID x 25cm) and an Agilent 1100 HPLC 
system (Agilent Technologies, Palo Alto, CA). The mobile phase was 0.2M 
Phosphate buffer, pH7.0 and 50 pL samples were injected at a protein concentration 
of 2mg/mL. The column was operated at lmL/min at room temperature. Fragment 
peaks eluting at the tailing edge of monomeric antibody peak were integrated using 
the tangent skim method, while aggregates were integrated using the perpendicular 
drop method.
2.3. Results
2.3.1 Ultra scale-down centrifuge technique development and verification of 
clarification performance predictions
The mammalian cells and associated debris used in shearing trials were taken from 
are the late decline phase of growth when only a small proportion (less than 10%) of 
cells are viable; the particle size distribution is unimodal (Figure 2.4) Exposure of a 
sample of this feed suspension to a maximum energy dissipation rate of 2.04 x 106 W 
kg'1 for 20 s, in the high-speed rotating disc device, leads to solids break-up and 
results in decreased particle size (for example a reduction in modal size from 11 to 8 
pm) and a bimodally distributed population. The consequence of this change on the 
efficiency with which solids can be removed by sedimentation, post-shear treatment, 
is described in the legend to Figure 2.4; a near doubling in the proportion of solids 
remaining in the supernatant following laboratory-scale centrifugation was observed 
(from 4.4 % to 7.5 % solids).
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Figure 2.4. Particle size distributions for mammalian cell broth exposed to shear in 
the rotating-disc device: ■  non-sheared; O sheared at an equivalent energy 
dissipation rate of 2.04 x 106 W kg'1 for 30 s. The area under the graph between any 
two sizes is equivalent to the volume of particles in that size range.
Solids remaining in the supernatant after centrifugation (OD basis, see equation 2.1): 
non-sheared, 4.4% ± 0 . 1  sd based on four replicates; sheared, 7.5% ± 0.4 sd. 
(Samples were spun in the laboratory centrifuge under the following conditions, N = 
71.7 rps, t = 1410 s, V = 40 mL, giving a V/t.E value of 2.5 x 10'8 m s '1).
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In practical terms the increased level of fine solids in the supernatant will reduce the 
filterability of the process stream due to blinding and could cause increased pressure 
drops across chromatography columns, due to fouling, if not eliminated prior to 
purification operations.
Figure 2.5 shows a visual (light microscopic) comparison between pre-shear NSO 
mammalian cells (Figure 2.5 (a)) and a sample after exposure to a maximum energy 
dissipation rate of 3.67 x 105 W kg'1, generated in the high-speed rotating disc device 
(Figure 2.5 (b)). Arrows 1 & 2 show damaged cells whose presence may be 
attributable to shear forces in the rotating disc device; while Arrow 3 shows an 
example of a debris particle with a diameter of less than 5 pm, corresponding to the 
smaller peak in the sheared sample particle size distribution (Figure 2.4).
A reduction in clarification performance is observed for samples exposed to shear for 
5 s (Figure 2.6) No further significant reduction in clarification efficiency was 
observed when samples were exposed to shear for between 5 and 30 s. Some further 
evidence of additional attrition was observed at longer exposure times (up to 50 s). 
All subsequent rotating disc shear experiments were limited to exposure times of 20 
s to allow reproducible operation to be more easily achieved and to avoid excessive 
break-up at longer times. This ensures sufficient time for exposure of the entire 
sample to the highest shear region at the tip of the disc for all the rotational speeds 
used (Boychyn et al., 2001) based on the mixing time.
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(b)
Figure 2.5 -  Light micrographs of NSO cells, (a) pre-shear and (b) after shearing in 
the rotating disc device at 3.67 x 105 W kg'1.
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Figure 2.6. Dependence of the percentage of solids remaining in the supernatant
following centrifugation on the duration of shear exposure prior to centrifugation.
All particle damage appears to occur within the first 5 s of shear (%2 >99.5%, t > 5 s).
Mammalian cell broth samples were exposed to an equivalent maximum energy
dissipation rate of 3.67 x 105 W kg'1. Sheared samples were spun in the laboratory
centrifuge under the following conditions, N = 66.7 rps, t = 1200s, V = 10 mL giving
8 1a value of V/t.X = 2.42 x 10' m s ' .  Data points and error bars indicate mean values 
and propagated standard errors for triplicate measurements respectively.
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The percentage of solids failing to sediment during centrifugation increases with the 
maximum energy dissipation rate during shearing (Figure 2.7). The result is 
attributed to higher rates of energy dissipation leading to the attrition of a greater 
proportion of the cell debris and a corresponding increase in the concentration of 
fines in the supernatant; such fines that cannot be sedimented under the centrifuge 
conditions tested. The extent of the reduction in clarification performance with 
increased shear stress diminishes as the number of susceptible cells decreases.
CFD analysis has allowed quantification of complex flow fields in an 
industrial disc stack centrifuge comparison with those found in the high-speed 
rotating disc device (Boychyn et al., 2004). As a consequence, the operating 
rotating-disc device could be used to mimic the effect on shear-sensitive solids of 
conditions in the centrifuge feed zone.
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Figure 2.7. Dependence of the percentage of solids remaining in the supernatant 
following centrifugation on the maximum energy dissipation rate to which the 
mammalian cell broth sample is exposed prior to centrifugation. Mammalian cell 
broth samples were sheared for 20 s in the rotating disc device and centrifuged under 
the following conditions, N = 66.67 rps, t = 1200s, V = 10 mL, giving a value of 
V /t.I = 2.42 x 10~8 m/s. Data points indicate mean values; and error bars represent 
propagated standard errors for triplicate measurements. Least squares best fit given 
using exponential relationship.
Figure 2.8 shows that the percentage of solids remaining in the supernatant, 
following centrifugation, increases between 1.5 and 2.8 fold with the V/t.Zratio, for 
unsheared samples and for samples exposed to maximum energy dissipation rates of 
1.95 x 104 W kg'1 and 3.67 x 105 W k g 1. Figure 2.8 shows that subjecting feed 
samples to increasing magnitudes of shear reduces the proportion of cell debris 
recovered over a range of centrifuge conditions as predicted in Figure 2.7. In each of 
these experiments the ratio V/tZ was adjusted by varying the time of centrifugation, 
t. The relationships are linear in all cases except for the samples exposed to the 
higher energy dissipation level at the low values of V/tZ. A linear relationship in 
these probability-log plots indicates that the volume-based particle size distribution 
is Gaussian. Evidently the significance of the fine particles formed under high stress 
conditions and the resultant bimodal relationship becomes noticeable at the greater 
levels of centrifugation.
Clarification data from two industrial-scale disc-stack centrifuges of equivalent size 
but with different feed zone configurations, are shown in Figure 2.9 which compares 
the industrial data to predictions of industrial-scale performance based on ultra scale- 
down experiments made by the extrapolation of the least squares fits given in Figure 
2.8. Industrial-scale data from the Alfa Laval BTPX 205 disc-stack centrifuge with a 
standard feed zone configuration correlates with laboratory-scale data predictions at 
all but the lowest feed flow rate for material pretreated at the highest shear rate. The 
leveling-off in solids removal at equivalent centrifuge conditions, at low V/tZ or Q/Z 
values, is not observed. The leveling-off in solids removal observed for the 
laboratory centrifuge at the lowest V/tZ value studied after material exposure to high 
shear rates is not reproduced for the industrial-scale centrifuge. Effects such as
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aggregation of the very fine debris in the static test tube centrifuge will lead to 
deviations, i.e. where the continuous flow nature of the disc stack prevents such 
effects occurring. Means of preventing such re-aggregation are currently under 
investigation. Otherwise good agreement is observed for the full range of 
extrapolated conditions for the low shear predictions and the recovery achieved in 
the Alfa Laval BTPX 305H with hermetic feed configuration. It is appropriate to 
note here the results of Lander et al. (2005), obtained using a CARR Powerfuge™ 
type centrifuge in which high feed zone stresses may be expected to lead to loss of 
clarification. In the paper, the inference is that no cell damage occurs. However, the 
low clarification efficiencies obtained are indicative of a high background of 
difficult-to-settle solids. In addition, the use of higher separation capabilities (Q/Z ~ 
10'9 ms'1) is likely to have been sufficient to mask effects of cell break up.
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Figure 2.8. Relationship between the % solids remaining and the ratio of equivalent 
flow rate to centrifuge separation area, plotted on probability-logarithmic axes for 
ultra scale-down method. Mammalian cell broth exposed to the following shear 
conditions in the rotating disc-device: ▲, A , non-sheared; • ,  O 1.95 x 104 W kg"1; 
■ , □  3.67 x 105 W kg'1. Symbols represent means of two sets of replicate 
measurements, error bars represent propagated standard errors for triplicate 
measurements. Open and closed symbols represent two separately produced 
fermentation broths. Solid lines represent the line of best fit for each data set.
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Figure 2.9. Relationship between the % solids remaining and the ratio of equivalent 
flow rate to centrifuge separation area, plotted on probability-logarithmic axes for 
industrial scale centrifugation: ■ , Alfa Laval BTPX 205; • ,  Alfa Laval BTPX 
305H. Solid lines represent ultra scale-down predictions (Figure 2.8), dashed lines 
represent extrapolations of these predictions. Zero shear ultra scale-down line also 
given for reference.
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2.3.2 Centrifugation Windows of Operation
Data acquired from ultra scale-down experiments can be presented as in Figure 2.8; 
however, converting such information into a format permitting process design 
decisions can be difficult. It would be advantageous to use these data to define an 
“operating space” within which a design engineer could be confident that specified 
design parameters could be achieved. Figures 2.10(a) and 2.10(b) show how such 
operating windows can be generated for centrifuge process design. The x-axis of the 
operating window shows increasing equivalent settling area (2) while the y-axis 
shows increasing volumetric flow rate (Q). In Figure 2.10(a) the shaded region 
shows a possible operating space, confined between two lines corresponding to 
lower and upper flow rate constraints. Below the lower flow rate constraint the 
process fluid temperature will increase as heat generated by the friction within the 
centrifuge is dissipated into the slow moving process stream. This would be 
unacceptable from a processing perspective as it would be likely to lead to 
denaturation of the protein product. The upper flow rate constraint represents the 
maximum achievable flowrate. The limiting upper and lower flow rate values 
increase as the size of the centrifuge increases.
In contrast to Figure 2.10(a), the shaded region of Figure 2.10(b) shows a 
performance space. Within the shaded region, a solids carryover of 1.5% can be 
achieved. The clarification constraint that encloses the performance space has been 
determined using the ultra scale-down centrifuge data presented in Figure 2.8. The 
line of best fit from the data generated by operating the rotating disc device at an 
energy dissipation rate of 3.67 x 105 W kg’1 was extrapolated to a solids carryover 
value of 1.5% and the corresponding equivalent flow rate to equivalent settling area
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(V/t.27) ratio determined to be 6.8 x 10'9 m.s"1 (Figure 2.11). Extrapolation of this line 
of best fit is questionable because of the failure of the data points at the equivalent 
flow rate to equivalent settling area (V/tJ7) ratio of 1.04 x 10'8 to lie on the line. The 
reasons for this are discussed in Section 2.3.1 along with Figure 2.8. Data from the 
large-scale (Figure 2.9) suggest the relationship should continue to be linear and 
hence the linear extrapolation is used to here for the purposes of demonstrating the 
windows of operation approach. The clarification constraint illustrates this ratio over 
a range of equivalent settling areas and flow rates. It assumes that clarification 
performance obeys the sigma theory of centrifuge scaling which may not be true for 
a process stream containing shear sensitive solids, as larger centrifuges are likely to 
generate higher shear forces, cause greater solids break-up and hence clarify the 
process stream less well than sigma theory would project.
An operating window generated when the clarification performance 
constraint is superimposed on the operating constraints is given in Figure 2.10(c). 
The performance space fails to overlap with the operating space, showing clearly 
that the required level of performance cannot be achieved using a centrifuge with a 
feed zone in which this level of energy dissipation occurs. The design engineer can 
overcome this problem by sacrificing clarification performance in order to achieve a 
performance space that intersects with the operating space.
Figure 2.10(d) shows the outcome of increasing the performance constraint to 
a value of 3.5% solids carryover. The region of overlap shows the flow rates at 
which target clarification will be achieved for any given equivalent size. Relaxation 
of the performance constraints does not, however, come without cost. In this case, 
increasing the clarification limit means that more than twice the volume of solids are 
carried over from the centrifugation; these solids must be subsequently by (eg. depth
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filtration) in order avoid solids fouling during the affinity capture chromatography 
step. Associated increases in the depth filtration area required to remove this 
particulate matter would substantially add to processing costs.
Impact of switching to a soft feed centrifuge with a feed zone that generates a 
maximum energy dissipation rate of 1.95 x 104 W kg'1, as determined by the ultra 
scale-down centrifuge technique while maintaining the original performance 
constraint of 1.5 % solids carryover is shown in Figure 2.10(e). The resulting 
operating window shows that not only can the desired clarification performance be 
achieved by this technological shift but also that it can be achieved over a broader 
range of flow rates. This larger operating window indicates a more robust centrifugal 
clarification process.
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Figure 2.10 (a) showing how an operating window can be constructed. An (■ ) 
operating space is defined between two lines corresponding to lower and upper flow 
rate constraints, (b). an operating window. The coloured region Q ) represents flow 
rate to equivalent settling area ratios allowing a maximum solids carryover of 1.5 % 
for a centrifuge with a feed zone maximum energy dissipation rate of 3.67 x 105 W 
kg_1.(c) The figure shows the constructed operating window with the performance 
space superimposed over the top of the operating space. In this case the two spaces 
have failed to overlap, indicating that this centrifuge cannot deliver the desired level 
of clarification.
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Figure 2.10 (cont.) (d) By adjusting the performance constraint to allow 3.5% solids 
carryover, overlapping performance and operating constraints produce an operating 
window (H ). (e). Replacing the normal feed centrifuge with a soft feed centrifuge 
allows the original performance constraint of 1.5% solids carryover to be achieved 
and gives a larger operating window, demonstrating a more robust process.
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Figure 2.11. Method for converting the data from ultra scale-down experiments into 
windows of operation.
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2.3.3 Product and process stream comparability study
The clarification results indicate that the performance of the industrial centrifuge can 
be predicted using the ultra scale-down centrifuge with appropriate pre- 
centrifugation shearing of the process suspension. It is, however, important to show 
that antibody levels and structure are comparable at both scales not least because it is 
desirable to use the supernatant from the ultra scale-down device to develop 
processes for subsequent unit operations such as ion-exchange and gel permeation 
chromatography steps.
Table 2.1 compares ultra scale-down predictions of normalized supernatant 
composition with industrial scale data. The levels of solids (debris) in the 
supernatant is seen to increase with increasing shear stress. An increase of 20% in 
the level of protein in the centrate is observed from the ultra scale-down centrifuge 
pre-sheared with a maximum energy dissipation rate of 3.67 x 105 W kg'1 which may 
indicate that at high levels of shear cell disruption and the release of subcellular 
proteins occurs. However, in general the level of DNA and product impurities do not 
appear to increase. The cell viability in the feed suspension at the point of harvest 
was low and it is likely that the majority of the cell contents had already been 
released so that the additional contaminant release caused by cell disruption in the 
centrifuge feed zones or in the feed zone mimics was relatively insignificant.
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USD
0
W kg"1
USD 
1.95 x 104 
W kg'1
Alfa Laval 
BTPX 305H
USD 
3.67 x 105 
W kg"1
Alfa Laval 
BTPX 205
MAb 1 0.89 1.00 0.99 1.02
Protein 1 0.92 1.04 1.20 0.95
DNA 1 1.00 0.97 1.01 0.78
Debris 1 1.32 1.42 3.95 3.94
Table 2.1. Composition of supernatant obtained from industrial-scale and ultra scale- 
down (USD) centrifugation mimics. %Solids remaining measured at V/t.Z or Q/c.L 
= 2.42 x 10'8 m/s. Laboratory centrifuge conditions were as follows: N = 66.67 rps, t 
= 1200 s, V = 10 mL. Maximum energy dissipation rates generated during pre­
shearing in the rotating disc device are given (W kg"1).
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A further concern is change in protein structure associated with exposure to air- 
liquid interfaces in well-mixed regions (Axelsson, 1999) While it is recognized that 
antibodies will have been exposed to such conditions within the cell culture vessel, 
the intensity of fluid mixing in the centrifuge feed zone is significantly different. 
Basic analysis of antibody structure is performed at Lonza Biologies by SDS-PAGE, 
iso-electric focusing and gel-permeation HPLC. The activity of products can be 
assessed by ELISA techniques or cell-based assays, however, these methods have 
not been developed for the cB72.3 antibody used in these experiments. Sophisticated 
product analysis techniques such as mass spectroscopy are available but are beyond 
the scope of this thesis.
Figure 2.12(a) shows the results of capillary-aided gel electrophoresis for the cB72.3 
antibody, prior to centrifugation (lanes 1 & 6), following ultra scale-down 
centrifugation under three different shearing conditions (lanes 2, 3 and 4 & 7, 8 and
9) and following centrifugation in the Alfa Laval BTPX 205 (lanes 5 and 10). Under 
reducing conditions (lanes 1-5) the heavy and light chains have the expected 
molecular sizes of 62 and 25 kDa, respectively. Under non-reducing conditions, the 
assembled antibody has a molecular size again as expected of 159 kDa.
Very similar band patterns are obtained under reducing and non-reducing 
conditions for samples from fermentation broth, ultra scale-down centrifugation 
supernatant and industrial centrifuge supernatant, indicating that the hydrodynamic 
conditions experienced by the antibody during any of the conditions investigated did 
not affect the protein size by cleavage of peptide bonds.
IEF profiles of purified antibody from the supernatant of the ultra-scale 
centrifuge, under the three shearing conditions investigated are shown in Figure
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2.12(b). The technique is used to demonstrate that no structural changes such as loss 
of N-terminal lysine residues which would result in an altered charge profile have 
occurred; capillary aided gel electrophoresis would be insufficiently sensitive to 
detect such changes. Samples of cell culture broth and supernatant from the Alfa 
Laval BTPX 205 centrifuge have been provided for reference. The p i  profiles of 
each antibody sample are comparable, displaying four major bands in the range 6.55 
to 7.35 indicating that no structural changes leading to altered charge profile have 
occurred during the ultra-scale or industrial scale clarification processes. This result 
is significant in that it bolsters the decision to use ultra scale-down centrifuge 
supernatant for the development of downstream chromatographic steps such as ion- 
exchange separations.
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Figure 2.12(a). Analysis of the cB72.3 antibody from ultra scale-down and large-
scale centrifuge supernatants. Samples analyzed by reducing (Lanes 1-5) and 
non-reducing (Lanes 6-10) capillary gel electrophoresis, after filtration and affinity 
(Protein A) separation. Reference samples prepared by laboratory centrifugation at 
3200 g, 600 s (Lanes 1 & 6). Ultra scale-down centrifugation with feeds exposed to 
equivalent shear rates o f zero shear (Lanes 2 & 7), 1.95 x 104 W kg’1 (Lanes 3 & 8), 
and 3.67 x 105 W kg '1 (Lanes 4 & 9). Alfa Laval BTPX205 supernatant (Lanes 5 &
10).Lane L represents molecular weight markers.
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Figure 2.12(b). Samples analysed by isoelectric focusing after filtration and affinity 
(Protein A) separation. Reference sample prepared by laboratory centrifugation at 
3200 g, 600 s (Lane 2). Ultra scale-down centrifugation with feed exposed to 
equivalent shear rates o f zero shear (Lane 3), 1.95 x 104 W kg '1 (Lane 4), 3.67 x 105 
W kg'1 (Lane 5). Alfa Laval BTPX205 supernatant (Lane 6). p i  markers (Lanes 1 &
7)
104
The relative proportions of antibody aggregates, monomer and fragments in cell 
culture broth, ultra scale-down supernatant and industrial supernatant samples, as 
determined by gel-permeation HPLC, are shown in Figure 2.12(c). Both ultra scale- 
down and industrial samples show the same relative proportions (to within ±1%) of 
each species indicating that the product generated at all scales investigated is 
comparable, with respect to the levels of aggregated and cleaved product.
The gel-permeation HPLC results show that samples from the ultra scale-down 
centrifuge exposed to increasing levels of shear contain a greater proportion of 
fragments. These fragments, which can be observed in lanes 6-10 (non-reduced 
antibody) in Figure 2.12(a) correspond in size to half antibodies (87 kDa), consisting 
of one light and one heavy chain. These results suggest that hydrodynamic forces 
experienced by the antibody in the rotating-disc device may split the monomer. It is 
hypothesized that the fraction of the B72.3 antibody which lacks covalent 
interactions between the heavy chains and which is maintained as a four-chain 
structure via non-covalent bonds (Aalberse & Schuurman, 2002) may be susceptible 
to shear effects. Losses of recombinant proteins, specifically, molecular level 
changes in product properties, due to hydrodynamic conditions in processing 
equipment at the molecular level are the subject of further investigation (Qvist et al., 
2006). While the rotating disc device employed here provides very important 
insights into the centrifugation process, it is possible that further insight into 
subsequent, high resolution bioprocessing operations may be gained by detailed 
molecular analysis.
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Aggnagates Moncinters Fragments
Mean
(%}
SD Mean(%) SD
Mean SD
Cell Culture Broth 0.20 0.002 99.80 0.003 0.00 0.000
USD Centrate exposed 
to 0 W kg'1 0.22 0.003 99.78 0.003 0.00 0.000
USD Centrate exposed 
to 1.95 x 104W kg'1 0.18 0.001 99.45 0.003 0.37 0.003
USD Centrate exposed 
to 3.67 x 10s W k g 1 0.16 0.002 98.86 0.007 0.98 0.005
Alfa Laval BTPX 205 0.48 0.002 99.51 0.003 0.01 0.001
Figure 2.12(c). Samples analyzed by gel permeation HPLC after filtration and 
affinity (Protein A) separation.
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2.4 Conclusions
The use of data generated using the ultra scale-down centrifugation technique 
facilitates predictions of industrial-scale disc stack centrifuge clarification 
performance over a range of operating flow rates. The accuracy of these predictions 
is increased when the hydrodynamic forces in the feed zone of the industrial-scale 
centrifuge are mimicked using a high-speed rotating disc device. Windows of 
operation can be used, in conjunction with ultra scale-down methodologies, to allow 
rapid decisions to be made regarding process design. The ultra scale-down centrifuge 
has been shown to generate supernatant representative of that produced at the large 
scale. This material can be used for the study of downstream operations such as 
filtration and chromatography processes, in an effort to elucidate the impact of 
centrifuge operating variables on the complex interactions between centrifuges and 
purification equipment.
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Chapter 3 -  Verification of the ultra scale-down centrifugation technology by 
comparison of predictions with the performance of a manufacturing-scale, disc- 
stack centrifuge, used to harvest a 20,000 litre cell culture bioreactor. 
3.1 Introduction
In the previous chapter the ultra scale-down technique was used to mimic the 
performance of normal and soft feed centrifuges with equivalent separating areas of 
11,350 m . Centrifuges in the pilot plant were used to remove the Lonza Biologies 
NS0 cell line 6A1 (100)3 from cell culture broth produced in a 500 L fermentation in 
the Lonza facility at Slough, UK. This section describes a trial in which the ultra 
scale-down centrifugation technique was used to mimic the performance of an Alfa 
Laval BTAX 215 continuous-flow, disc-stack centrifuge with an equivalent 
separating area of 197,900 m2 and a standard feed zone configuration, which is used 
in the manufacturing process for the harvesting of a 20,000 L cell culture reactor 
containing an undisclosed customer CHO cell line.
It was anticipated that this larger scale centrifuge would perform less well 
than the pilot centrifuge as the tip-velocity of critical structures within the feed zone, 
where initial contact and acceleration of the process stream occurs, would be relative 
orders of magnitude higher and hence would dissipate a greater amount of energy 
into the process fluid. In order to improve clarification performance at the large- 
scale, experiments were carried out at different bowl speeds, with a view to reducing 
the tip-speeds and shear rates to which cells and cell debris would be exposed. This 
study allowed the validation of the ultra scale-down technology at a larger scale and 
with a different cell line.
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3.2 Materials and Methods
The experimental overview and calculations of solids remaining were as detailed in 
the previous chapter.
3.2.1. Cell Culture Broth'. Experiments were carried out using cell culture broth 
containing a customer Chinese Hamster Ovary (CHO) cell line expressing a 
monoclonal antibody product. The broth was produced using a 20,000 L fed-batch, 
stirred-tank manufacturing fermenter. All centrifugation studies were undertaken 
using broth from the late decline phase of growth, 14 days after inoculation.
3.2.2. Rotating-disc device: The rotating-disc device was operated as detailed in the 
section 2.2.5 at maximum energy dissipation rates of 1.95 x 104, 1.08 x 105 and 3.67 
X 105 W k g ' 1
3.2.3. Laboratory-scale centrifugation'. IEC Centra CL3 laboratory centrifuge with 
the ‘243’ swing-out rotor (IEC International Equipment Company, Massachusetts, 
USA). Polypropylene centrifuge tubes, 15 mL, filled with 10 mL of broth were used. 
Following each centrifuge run the uppermost 5 mL of supernatant was removed by 
pipette, taking care not to disrupt the sediment at the bottom of the tube. 
Centrifugation conditions are detailed in section 3.3. Well-spun samples providing 
solid-free supernatant were prepared by centrifugation at 13 200 rpm for 15 minutes.
3.2.4. Industrial-scale centrifugation: The mammalian cell culture broth was 
harvested using an Alfa Laval BTAX 215 disc stack centrifuge (Alfa Laval, Lund,
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Sweden) by over-pressurizing the vessel with compressed air. The centrifuge was 
variously run at bowl speeds of 5000, 5500 and 6000rpm and flow rates of 3300, 
4800 and 6000 L/h respectively. Supernatant samples were taken once the centrate 
optical density had stabilized.
3.2.5. Measurement o f  remaining solids: As described in section 2.2.6.5 the 
proportion of solids remaining in the supernatant following centrifugation was 
determined by optical density measurements of feed, supernatant and well-spun 
samples, using a Shimadzu UV160U UV/Vis spectrophotometer at 550 nm, blanked 
with phosphate-buffered saline, pH 7.4.
3.3. Results
Figure 3.1 shows that, as the ratio of equivalent flow rate to settling area is increased 
(using the ultra scale-down technique), the proportion of solids remaining in the 
centrifuge supernatant increases, as the particles have less opportunity to sediment. 
This trend is consistent with data presented in Figure 2.8. Prior to centrifugation 
samples were exposed to four levels of energy dissipation rate in the rotating-disc 
device.
These results again demonstrate that as the magnitude of these hydrodynamic forces 
is increased, the proportion of solids failing to sediment increases. From previous 
results this observation is attributed to the general reduction in particle size and the 
build up of a small population of fine solids (particle size less than 5 pm) as shown 
in Figure 2.4.
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Figure 3.1. Relationship between the % solids remaining and the ratio of equivalent 
flow rate to centrifuge separation area, plotted on probability-logarithmic axes, for 
ultra scale-down method. Mammalian cell broth exposed to the following shear 
conditions in the rotating disc-device: A , non-sheared; # ,  1.95 x 104 W kg"1; ♦ 1.08 
x 105 W kg'1 ■ , 3.67 x 105 W kg"1. Symbols represent the means of two 
measurements and bars represent the range of measurements.
111
USD (3.67 x 105W kg'1)
1 0 -
USD (1.08 x 105 W k g ' )
o>
USD (1.95 x 104 W kg'1)
non-sheared
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Figure 3.2. Relationship between the % solids remaining and the ratio of equivalent 
flow rate to centrifuge separation area, plotted on probability-logarithmic axes, for 
both the ultra scale-down method and the industrial scale, continuous-flow, disc- 
stack centrifuge. Solid lines represent ultra scale-down predictions from Figure 3.1. 
Alfa Laval BTAX 205 operated at a bowl speeds of 5000 rpm (A ) 5500 rpm (□ ) 
and 6000 rpm (O).
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Figure 3.2 shows data from the BTAX 205 operated at bowl speeds of 5000 rpm, 
5500 rpm and 6000 rpm. The data points at all three bowl speeds approximate the 
performance of the ultra scale-down centrifugation method in which samples were 
sheared, prior to centrifugation, at a maximum energy dissipation rate of 3.67 x 105 
W kg'1. Figure 2.9 shows that the performance of the Alfa Laval BTAX 205 
centrifuge was mimicked by subjecting the cell culture broth to the same shear rate 
as used for the BTPX 205. This observation was unexpected as the tip velocity of the 
disc would be greater in the Alfa Laval BTAX 205 centrifuge, even at lower 
rotational speeds as indicated in Table 3.1. The “critical structure” of the disc stack 
centrifuge feed zone was taken to be the zone in which fluid flows up, past the 
lowest disc, into the bowl; CFD analysis has previously shown that this is the region 
of maximum energy dissipation (Boychyn et al, 2004).
Figure 3.2 shows that the extent of shear damage is not decreased by 
reducing the bowl speed, as data points from the large-scale centrifuge operated at 
5000 rpm, 5500 rpm and 6000 rpm are all in agreement with the ultra scale-down 
prediction, based on samples pre-sheared at a maximum energy dissipation rate of 
3.67 x 105 W kg1. The explanation for these observations can possibly be found in 
Figure 2.7 which shows that at high maximum energy dissipation rates, further 
increases in energy dissipation do not lead to significant increases in solids carry­
over; it is postulated that solids susceptible to shear damage are disrupted at lower 
energy dissipation levels.
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Alfa Laval 
BTPX 205
Alfa Laval 
BTAX 205
Use
Development
Pilot
Machine
Manufacturing
Bowl Volume 
(L)
3.1 52.0
Bowl Speed 
(rpm)
9650 5000 5500 6000
Equivalent Settling 
Area (m2)
11,350 137,500 166,300 197,900
Disc outer diameter 
(m)
0.17 0.43 0.43 0.43
Tip velocity 
(m s ‘)
85 113 124 135
Table 3.1 Comparison of pilot- and large-scale centrifuges, indicating variation in tip 
speed with scale and bowl speed.
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It may be that the hydrodynamic environments in the feed zones of both the BTPX 
205 and the BTAX 205 are both sufficiently aggressive to disrupt all susceptible 
solids and that reducing the tip speed of the BTAX 205 to 5000 rpm fails to reduce 
maximum energy dissipation in the feed zone to levels that will significantly impact 
on the recovery of solids in this feed stream. This observation of equivalent levels of 
cell disruption in the feed zones of the BTPX 205 and the BTAX 205 is significant, 
in that it suggests that scaling between the two centrifuges will be consistent with 
sigma theory whereas reduced clarification performance may have been expected at 
the large-scale at equivalent Q/E values due to the effect of increased cell disruption.
3.4 Conclusions
The results presented in this chapter are further evidence that the ultra scale-down 
centrifugation method can be used to accurately predict the performance of large- 
scale, continuous-flow, disc-stack centrifuges. Here the approach has been verified 
using material from a different fermentation carried out with a different cell line and 
at a ten-fold greater scale than in Chapter 2. The results indicate that the centrifuge 
used to harvest the 20,000 L bioreactor does not disrupt cells to a greater extent than 
that used to harvest the 2,000 L bioreactor. However, taking into account the results 
presented in Chapter 2 it is hypothesized that this is because only a small proportion 
of the total solids in the bioreactor at the harvest point is shear-sensitive and not that 
the larger and pilot scale centrifuges generate similar levels of energy dissipation.
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Chapter 4 -  The use of an ultra scale-down chromatography column for the 
prediction of product elution profiles and its verification by comparison with an 
elution profile from a pilot-scale chromatography column.
4.1. Introduction
The volume of buffer required to elute product from a production scale 
chromatography column is frequently a concern, especially at very large scales. 
Laboratory experiments are used to predict elution volumes; however, the accuracies 
of these predictions are often inadequate for the purpose of specifying large-scale 
facility design. The consequences of this uncertainty in determining elution volumes 
are severe for a manufacturer. At the large scale, receiving tanks of an appropriate 
size must be available into which the eluted peak can be collected. As the volume of 
the elution peak is frequently determined at the point of elution by the absorbance of 
the column effluent at 280 nm, and not prior to the operation of the production, 
column, it is conceivable that an unexpectedly large elution volume could exceed the 
capacity of the tank designated to receive it. In order to prevent associated product 
loss, processes are developed using excessively large receiving tanks as a 
contingency measure, but contributing to manufacturing process inefficiencies.
The volume into which the product elutes determines the concentration of the 
eluted product. Eluted product concentration is an important design variable used to 
develop subsequent process steps such as membrane operations. Unexpectedly dilute 
feed streams to membrane operations demand longer processing times, as parameters 
such as membrane area and flow rates are fixed in advance. Conversely, large-scale 
chromatographic processes yielding lower elution volumes than expected and
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increased maximum product concentrations can be observed upon scale-up despite 
maintenance of a constant bed height. The reasons for this are poorly understood but 
the magnitude of the problem is both product- and buffer-specific. High product 
elution concentrations can, in turn, increase the degree of product aggregation. Two 
possible hypotheses to explain scale-dependent product aggregation upon elution are 
(i) that as processes move to larger scales, where extra-column volumes are small 
relative to the total volume of the system, extra-column dispersion is minimized 
leading to tall, concentrated elution peaks or (ii) that increasing the column diameter 
may alter the packing characteristics of the bed due to the loss of wall support (Sofer 
& Nystrom, 1989). It is thought that columns with diameters of less than 20 mm, 
which are frequently used in process development, may have less compressed beds 
and greater void volumes, which may result in reduced product concentrations and 
aggregation upon elution. Chromatographic aggregation removal steps developed in 
the laboratory must clear aggregates from the product stream at the large-scale, to 
pre-specified limits, if not, the batch must be discarded to avoid compromising 
patient safety.
Predicting the volume and product concentration of the eluate of a 
chromatographic step at increasing scales is of great importance to 
biopharmaceutical manufacturers and yet is inadequately covered in the published 
literature. This chapter describes the use of ultra scale-down methodologies for the 
prediction of eluate volumes and product concentration from an affinity 
chromatography step for capturing antibodies from clarified cell culture supernatant.
Theoretical considerations in zone broadening: Differential migration provides the 
basis for chromatographic separations; however, the effectiveness of
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chromatography is also dependent on the degree of zone spreading. Ideally each 
solute should pass from the column at a different instant in time, however, in practice 
this does not happen and elution bands spread out so that each solute takes a finite 
period of time to pass from the column. Zone spreading can occur by axial diffusion, 
eddy diffusion and local non-equilibrium effects.
Axial diffusion of molecules along the length of the chromatography column 
broadens the peak by transporting solute upstream and downstream away from the 
region of greatest concentration at the centre of the zone (Figure 4.1(a)).
Spreading by eddy diffusion is a consequence of the differing lengths of flow 
paths along which solute molecules will pass while traveling through the packed bed. 
Those solute molecules taking a more direct path through the column will travel 
ahead of the average rate of progress, while those taking a more tortuous path will 
travel more slowly (Figure 4 1(b)).
In chromatography, the local non-equilibrium effect is perhaps the most 
important cause of zone spreading. As a solute passes through a column, 
concentration within the zone increases from the front edge and reaches a maximum 
at the centre before decreasing to zero at the trailing edge (Figure 4.1b). Non­
equilibrium effects are caused by delays in mass transport of the product through the 
boundary layer and the liquid in the pores to the internal surface where adsorption 
takes place.
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D irection o f flow
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(a) (b)
Figure 4.1 showing the axial diffusion path from the zone of highest solute 
concentration and the differing flow paths that solutes can take contributing to zone 
spreading. Reproduced from Doran 1994.
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This delay prevents equilibration being reached between the liquid and solid phases 
and consequently the front edge of the pulse will travel down the column more 
rapidly than that which will follow it while the rear edge of the pulse will continually 
be stretched out as the solid phase will continue to lose solute molecules once the 
liquid phase concentration has reached zero (Doran, 1994).
Zone broadening is often analyzed using the concept of theoretical plates 
(Doran, 1994). A theoretical plate is an equilibrium stage with a magnitude of the 
same order as a resin particle. Although equilibrium is rarely reached in a 
chromatography column and thus, the concept is a poor reflection of conditions 
within the column, it provides a measure of zone spreading. The lower the height 
equivalent to a theoretical plate (HETP) the narrower the solute peak should be. A 
frequently used expression relating HETP to the linear velocity of the liquid (v) is as 
follows;
HETP = (A.va)  + (B.v) + C Equation 4.1
where A, B and C are experimentally determined constants. The first term, A, refers 
to molecular diffusion, B  results from mass transfer resistances and C originates 
from eddy diffusion effects (Doran, 1994). A graphical representation of the 
expression is given in Figure 4.2.
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Linear velocity, v
Figure 4.2 The relationship between linear flow rate and HETP. At low linear flow 
rates diffusion effects dominate and HETP decreases as the flow rate increases; 
however, at higher velocities mass transfer effects begin to dominate and HETP 
increases with increasing flowrate.(Illustrative figure generated using Equation 4.1 
and hypothetical values for constants A, B and Q  (Doran, 1994).
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Pulsed-input testing of packed chromatography beds is commonly performed in 
order to estimate the HETP as an indication of resin packing efficiency (Hoffman, 
1998). A pulse of tracer molecule, equivalent to 1-5% of the total column volume, is 
applied to the column inlet and the tracer concentration in the column effluent is 
monitored over time. The variance in the pulse of the tracer at the column outlet, cr2, 
is proportional to the distance travelled by the pulse, z. Hence HETP is a measure of
zone broadening per unit column length, as given by equation 4.2:
2
HETP = —  Equation 4.2
z
Alternatively, the number of theoretical plates, N, is often used as a measure of how 
well a chromatography column is packed and is related to HETP as follows:
2
N  = - Equation 4.3
HETP
The distance traveled by the solute pulse is usually substituted by the more easily 
determined retention volume, VR, which is the equilibration buffer volume delivered 
by the pumps, measured from the time when half the sample mass is applied to the
column to the time when half the sample mass is eluted from the column. Hence,
z V. v „ V
N = R
A,
R
J
Equation 4.4
Hence HETP on a chromatography column, of bed height, L, can be described as 
follows,
HETP — —  —----- —-  Equation 4.5
N  ( y  /N1 v Rj
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Two simplifications are often applied when determining the solute retention volume. 
The contribution of the pulse volume to the retention volume is often ignored if the 
pulse is small; however, if the pulse volume is not negligible the solute retention 
volume is set when half the sample volume has been injected. Also the contribution 
to broadening of extra-column volumes, in pipes from the injector to the column and 
from the column to the detector, is often ignored.
The assumption that zone broadening in extra-column volumes is 
insignificant is unlikely to be true, especially in the laboratory where standard 
chromatographic systems are frequently used. Decreasing the column bed height in 
order to minimize the volume of process material required for chromatography 
process development will increase the influence of extra-column broadening on the 
data acquired from such studies. There is a limit to the extent that extra-column 
volume can be minimized and hence the ratio of extra-column volume to column 
volume will increase with the degree of scale-down.
Extra-column broadening can be subdivided into dispersion in tubes, 
contributions of dead volumes, finite detector volume and dynamic behavior of 
transducers and electronics. Tubing introduces a symmetrical, Gaussian-type 
broadening (a?) to the sample, under the combined actions of molecular diffusion 
and the axial flow velocity profile.
Under laminar flow conditions broadening caused by tubing can be described
by
t r 2a 2 = —^ —  Equation 4.6
24 D m
where tR is the retention time, r the tube radius and Dm the molecular diffusion 
coefficient (Kaltenbrunner et al., 1997). Dead volumes introduce an exponential
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contribution to the band broadening (id ead ), which is a function of the dead volume 
(Pdead) and the flow rate (Q) as described by(Kaltenbrunner et al., 1997),
^  = V- ^ ~  Equation 4.7
Additionally the finite sensing volume of a detector introduces an additional 
symmetrical, rectangular broadening (^d) as described by,
V 2
cr] = — ~~t~ Equation 4.8
12 Q 2
where Vj is the sensitive detector volume. An exponential contribution to the band 
broadening is introduced by the finite response rate of the amplifier and recorder 
(xei). (Cram & Glenn, 1975). Assuming additivity of the variances, the total extra­
column broadening can be written as,
° d  = <y] + o f  + + r]ead + r;; Equation 4.9
o 'ywhere oex is the lumped extra-column dispersion and as is the variance of the initial 
injection profile. Assuming that the variances introduced by the electronics and the 
detector volume are negligible compared to other variances,
<  = c ;  + er,2 + t 2dead Equation 4.10
The total broadening ( o w 2) is the sum of column internal broadening (oa,l)  and the 
extra column broadening (aex ), le.
o-L, = °]oi + Equation 4.11
Defining the plate number, N, for a column, as
V 2
N  = - j -  Equation 4.12
o*co/
substitution yields the following expression,
<rL  = ^ f  + <d = ^  Equation 4.13
N  L
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which enables extra-column broadening (oex2) to be determined from a plot of total 
band broadening {atotai ) as a function of Vr , where VR is the retention volume 
(Huber & Rizzi, 1987). The work described in this chapter investigates the 
possibility of accurately determining the relative contributions of column and extra­
column broadening to elution profiles and using this information to make scale-down 
predictions for a pilot-scale chromatography column with column volume of 18.3 L.
The use of pulse inlet testing, although common for measuring column packing 
efficiencies, becomes impractical for very small columns (ie. column volumes of a 
milliliter or smaller) as pumps fitted to standard laboratory chromatography systems 
would be unable to accurately deliver sufficiently small pulses. Transition analysis 
provides a suitable alternative to pulse inlet testing for determining zone spreading, 
by measuring the response at the outlet of a column to a step change at the column 
inlet. Step changes in optical density, conductivity and pH can be used, with the 
relevant detector at the column outlet, to assess the condition of the packed bed. 
During a standard chromatographic cycle numerous transitions occur, allowing the 
quality of the bed to be easily assessed after each cycle in order to detect changes in 
bed quality over time (Larson et al., 2003).
4.2 Materials and Methods
4.2.1 Laboratory Studies
4.2.1.1 Packing and transition analysis. Five Tricorn columns, with internal 
diameter of 5 mm, were packed to bed heights of 20 mm, 53 mm, 102 mm, 145 mm
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& 205 mm, respectively, with rmp Protein A Sepharose 4FF (GE Healthcare) 
chromatography matrix using equilibration buffer at 150% of the operating flowrate 
of 1.5 m h '1. The experimental set-up is schematically illustrated in Figure 4.3. The 
columns were equilibrated with 50 mM glycine-glycinate, 250 mM sodium chloride, 
pH 8.0 before transition to the 100 mM glycine -  HC1, pH 3.5, initiated by switching 
of the pump valve. Effluent conductivity was monitored beyond the outlet of the 
column, as close to the fraction collector as possible. Once the conductivity 
transition (from high conductivity to low conductivity) had reached completion the 
column was re-equilibrated and the experiment repeated.
4.2.1.2 Elution profiles'. Elution profiles were generated from 53 mm and 157 mm 
columns by loading and eluting purified chimeric B72.4 antibody. Table 4.1 shows 
the operating conditions of the laboratory columns. Column flow rate was varied to 
maintain a constant column residence time of 0.1 h. Excess buffer was used to ensure 
that each stage had reached completion; thus buffer volumes are not indicative of 
volumes required at larger scales. Fractions (100 pL from the 53 mm and 300 pL 
from the 157 mm column) were collected into a 96-well plate. The fractions were 
analyzed on the basis of absorbance at 280 nm. Details of the columns used in this 
chapter are given in Table 4.2
Elution profiles at different flow rates were determined using the column of 
53 mm bed height, by repeating the above procedure at elution flow rates, without 
changing the operating flow rate for any other step.
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Figure 4.3 Schematic diagram of the chromatography system used in laboratory scale 
experiments.
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Step Buffer ColumnVolumes
Linear Flow Rate 
(m/h)
Equilibration
50 mM glycine- 
glycinate/
250 mM NaCl pH 
8.0
6 1.5
Product Load 0.50 mg/mL b72.3 antibody, pH 8.0 20
0.53 & 1.57 for the 5.3 
cm and 15.7 cm 
column bed heights, 
respectively
Post-Load
Wash
50 mM glycine- 
glycinate/
250 mM NaCl pH 
8.0
6 1.5
Elution
100 mM glycine 
hydrogen chloride 
pH 3.5
8 1.5
Strip
50 mM glycine- 
glycinate/
1.75 M NaCl, pH 8.0
10 1.5
Sanitization
_
6 M guanidine 
hydrogen chloride, 
pH 3.5
6 0.52
Re-
equilibration
50 mM glycine- 
glycinate/
250 mM NaCl pH 
8.0
6 1.5
Table 4.1. Operating conditions for the 0.5 cm diameter Tricorn columns with bed 
heights of 53 mm and 157 mm. The linear flow rate during the product loading phase 
was varied to give constant residence time.
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Bed height 
(cm)
Diameter
(cm)
Volume
(mL) Aspect Ratio Use
2 0.5 0.4 4.0 Transitionanalysis
5 0.5 1.0 10.0 USD
10 0.5 2.0 20.0 Transitionanalysis
15 0.5 2.9 30.0 Transitionanalysis
20 0.5 3.9 40.0 Transitionanalysis
15 40 18849.6 0.4 Pilot
Table 4.2. Summary of columns used in this chapter.
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4.2.2 Pilot Studies
4.2.2.1. Packing and transition analysis. A pilot-scale chromatography column, with 
internal diameter of 400 mm, was packed to a bed height of 146 mm with rmp 
Protein A Sepharose 4FF chromatography matrix (GE Healthcare) using 
equilibration buffer at 150% of the operating flowrate of 1.5 m h '1. As with the 
laboratory-scale columns, the pilot-scale column was equilibrated with 50 mM 
glycine-glycinate, 250 mM sodium chloride, pH 8.0, before a transition to the 100 
mM glycine -  HC1, pH 3.5 was initiated. The effluent conductivity was monitored 
beyond the outlet of the column; once the downwards conductivity transition had 
reached completion the column was re-equilibrated and the experiment repeated.
4.2.2.2. Elution profiles: The elution profile from the pilot-scale column was 
generated by loading and eluting purified chimeric B72.4 antibody. Loading of the 
columns to a level consistent with the laboratory columns was achieved by 
maintaining a constant column residence time of 0.1 h and an equal feed-to-column 
volume ratio. Equilibration, post-load wash, elution, column strip and re­
equilibration stages were carried out at 1.50 m.hf1 while the sanitization step was 
carried out at 0.52 m.h'1. During elution 15 mL samples of the eluate were collected 
at 2 L intervals and the absorbance (at 280 nm) determined to measure MAb 
concentration. Buffers used at the pilot-scale were as those used for the laboratory 
experiments with the exception of the strip buffer, which was replaced with 100 mM 
citric Acid, pH 2.1.
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4.2.3. Transition Calculation Methodology
Conductivity transition data were normalized by finding the maximum and minimum 
conductivity values over the course of the transition volume, subtracting the 
minimum from each value of the solute signal and dividing each of these values by 
the difference between the maximum and minimum values. &R/&V, the first 
derivative of the normalized conductivity response data array, R, and the totalized 
volume data paired with R, V, was estimated numerically using a moving average of 
the slope. Calculating &RI&V using a moving average interval produces a smooth 
transition shape and increases the accuracy of subsequent calculations (for sample 
calculation see Appendex 1).
Moment analysis of the transitions allows values for HETP and dispersion to 
be obtained from the entire solute response curve, without making any assumptions 
about the distribution of the curve, as follows,
HETP„ = ct2L
Ml
V^o
Equation 4.15
where <? is the variance as expressed as follows,
Equation 4.16
M 0
and Mo, Mi and M2 are the zeroth, first and second moments, respectively, with the 
integrals estimated by trapezoidal approximation according to equation 4.17, where 
R is the solute step response and k  is the moment number (for sample calculation see 
Appendix 1)
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M k =  IV* —  dV Equation 4.17
4.3 Results
4.3.1 Transition analysis of ultra scale columns
Conductivity transitions (A) for the five columns, plotted on a volume basis, and the 
first derivative (B) of the conductivity transitions are shown in Figure 4.4. In each 
case the conductivity drops from approximately 25 mS/cm to 0.5 mS/cm as the 
equilibration buffer (50 mM glycine-glycinate, 250 mM sodium chloride) is replaced 
by the elution buffer (100 mM glyine hydrogen chloride). This particular transition is 
part of the generic Protein A affinity chromatography step at Lonza Biologies. As the 
column heights and volumes increase, the transition residence volume also increases, 
as the distance between the pump valve (where the transition starts its course through 
the system) and the conductivity meter (where the transition is measured) increases. 
Furthermore, it can be seen that the gradients of the conductivity transitions become 
less steep, the height of the first derivative peak decreases and the peak width of the 
first derivative increases. The increase in the transition broadening with column 
length is attributable to the effects of axial and eddy diffusion, both of which will 
increase as the distance over which the transition passes increases. It can be seen that 
the first derivatives of the 145 mm and 205 mm bed height columns are less smooth 
than the others. This indicates that the moving average filter applied during the 
calculation did not include sufficient data.
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Figure 4.4. Regime analysis of laboratory chromatography systems, showing the 
effect of decreasing bed height on the retention volume and dispersion of the 
conductivity transition. From left to right curves correspond to bed heights of 20, 53, 
102, 145, 205 mm respectively. Each column had a bed diameter of 5 mm, was 
packed with Protein A Sepharose 4 FF resin and was attached to the same AKTA 
FPLC system with identical connecting tubing. A: conductivity data; B: first 
derivative of the conductivity data with respect to totalized volume, giving an insight 
into the maximum rate of change and dispersion associated with each curve.
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The data presented in Figure 4.4 are again presented in Figure 4.5, but plotted on the 
basis of column volumes. Thus presented the results show that the transition 
residence volumes increase with decreasing column height when normalized by 
column volume. This occurs because the extra-column volume, constant for all 
columns, constitutes a greater proportion of the total system volume for smaller 
columns. For the same reason, the transition gradients decrease and the width of the 
first derivatives increase with decreasing column size. The dispersion caused by the 
transition flowing through the extra-column volume makes up a larger proportion of 
total system dispersion for a smaller column.
Figure 4.6 shows the positive linear relationship between the column volume, Vc, 
and the retention volume, V r, of the transition, as determined by moment analysis of 
the transition curves presented in Figure 4.4. The relationship can be described as 
follows,
VR = s.Vc + Vex Equation 4.18
where e is the average column void fraction and Vex is the extra-column volume. 
From the intercept with the y-axis the extra-column volume was determined to be 
0.81 mL which represents a significant contribution to the total system volume 
particularly when operating the smallest column with a column volume of 0.4 mL. 
This value can also be determined by connecting the upper and lower column 
adapters; however, this was not technically possible with the particular columns used 
in this experiment. The gradient of the line is equal to the column void fraction 
which in this case was determined to be 0.97 which although quite high, may not be 
unrealistic since the solute was small ionic species and the matrix is highly porous.
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Figure 4.5. Regime analysis of laboratory chromatography systems showing the 
effect of decreasing bed height on the retention volume and dispersion of the 
conductivity transition. Data as for Figure 4.4 but using column volumes rather than 
total volume to compare performances. Curves from left to right are, respectively, 
bed heights of 205, 145, 102, 53, 20 mm. Each column had a bed diameter of 5 mm, 
was packed with Protein A Sepharose 4 FF resin and was attached to the same 
AKTA FPLC system with identical connecting tubing. A: normalized conductivity 
data; B: the first derivative of the conductivity data with respect to column volumes.
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Figure 4.6 -  Experimentally-determined relationship between retention volumes, Vr 
and total column volumes, Vc. Linear regression analysis yields Vr = 0.81 + 0.97 Vc 
corresponding to a void fraction of 0.97 and the extra-column volume of 0.81 mL
The result contrasts with that published by Kaltenbrunner et al. (1997) in which the 
system extra-column volume was determined to be 0.32 mL with a void fraction of 
0.47. Kaltenbrunner et a l used a different chromatography resin (Q-HyperD) in their 
experiments and a protein pulse under non-binding conditions.
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An alternative figure can be plotted using the same transition analysis data. If 
the retention volume of a transition is normalised with respect to the column volume 
as described in equation 4.19,
= —  Equation 4.19
where V r*  is the normalised retention volume of a transition, then equation 4.18 can 
be re-written as,
(  V ^ 1
VR * = e  + — ^  ~  Equation 4.20
\ * r c  J  L
where rc is the column radius and L is the chromatography bed height.
A plot of normalized retention volume ( V r * )  against reciprocal 
chromatography bed height (L'1) is shown in Figure 4.7. It should be reiterated that 
Figure 4.7 provides no additional information to that presented in Figure 4.6. 
However, it usefully summarizes the findings of Figure 4.5, showing that scaling- 
down by reducing column bed height increases the normalized retention volume, 
because the extra-column volume constitutes a greater proportion of the total system 
volume. The relationship between retention volume and transition dispersion, 
described by equation 4.13, is shown in Figure 4.8. The gradient of the line is equal 
to the number of plates per unit length of column (1/N = 0.0236). From the equation 
of the line can be determined for the retention volume equal to that of the void 
volume. Using equation 4.13 dispersion attributable to flow through the extra­
column volume for this system can be calculated to be 0.028 mL2. For small scale- 
down columns, the band broadening which occurs in the extra-column volume can 
dominate over total band broadening in the system.
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Figure 4.7. Fractional retention volume for columns of varying heights, determined 
from the conductivity transitions shown in Figure 4.6. The least squares best fit line 
(R2 > 0.99) has a slope of 4.1 cm, giving an extra column volume for the system of 
0.81 mL and an intercept of 0.97, equivalent to the void fraction of the bed, 
according to equation 4.20.
138
0.25 -i
0 .2 0 -
0.15-
0 . 1 0 -
0.05-
0.00
Retention Volume2, VR2 (mL2)
Figure 4.8. Plot of total band broadening versus retention volume. Equation of line, 
(/to ta l = 0.02355 + 0.00679 V r  (R2 > 0.99) From equation 4.13 the extra-column 
volume determined to be 0.81 mL.
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Total dispersion can be normalized by column volume and related to the normalized 
retention volume as follows,
= + %  Equation 4.21
iV Vc
where Vc is the chromatography bed volume (Vc = n rc L ). Substitution of equation 
4.20 and rearrangement expresses the normalized total dispersion as a function of the 
chromatography bed height, allowing the prediction of the total band broadening 
occurring in a column of any length on the same chromatography system:
£
Ma! + v N x r c2 j
L ] + n  2rc 4
V ‘
ex + a l
N
Equation 4.22
The data from Figure 4.8 are plotted according to Equation 4.22 as shown in Figure 
4.9. The figure illustrates how decreasing the bed height of the column significantly 
increases the zone spreading relative, to the size of the column.
The proportion of the total dispersion that is attributable to flow through the extra- 
column volume, for columns of different heights is shown in Figure 4.10. The figure 
shows that this proportion increases from 17%, for a column with a bed height of 
205 mm, to 86%, for a column with a bed height of 20 mm, illustrating the 
importance of accounting for extra-column broadening when making predictions of 
large-scale chromatography operations using very small volume columns.
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Figure 4.9. Normalized total dispersion for columns of varying bed height, showing 
increasing importance of dispersion at reduced bed heights. In the form of Equation 
4.22, the equation of the non-linear curve fit is 
(Jionl* = 6.39x l ° “3 + 5.43x 10_2L_I + 0.842 r 2 (R2 >0.99)
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Figure 4.10. Ratio of extra column broadening to total broadening, as a function of 
the column bed height, calculated using the regression lines from Figures 4.6 and 
4.8.
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4.3.2 Comparison of ultra scale-down columns with laboratory-scale columns
Developing the ultra scale-down approach for predicting elution volumes was 
performed in two phases. Firstly, a method to predict the performance of a laboratory 
column with an ultra scale-down was developed and then the approach extended to 
allow predictions of a pilot-scale column. Scaling-down the laboratory column by 
reducing the bed height represents only a small decrease in scale, however, it 
requires changing the parameter that along with linear flow velocity is traditionally 
kept constant during scaling and hence represents a considerable challenge. Figures 
4.11 and 4.12 show the elution profiles from the 53 mm and 157 mm bed height 
columns. Data points represent the mean product concentrations in each fraction 
based on replicate measurements and error bars represent one standard deviation 
from this mean. To further reduce the feed volume, it would have been preferable to 
use the 20 mm column to predict the product elution volume and concentration for 
large-scale columns; however, it was not possible to collect sufficient fractions to 
plot an elution profile from the smaller column. It was necessary to collect fractions, 
rather than use the on-line UV detector because the protein concentration during 
elution was sufficiently high to saturate the detector. The 157 mm column was used 
for the ultra scale-down column comparison as this is within the validated range of 
column bed heights used in this process at the manufacturing scale (150 mm ± 1 0  
%).
Figure 4.11 shows the concentration of product in collected fractions on a volume 
basis while Figure 4.12 shows the same data normalized for column volumes. There 
are similar trends to those observed for the conductivity transitions presented in
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Figures 4.4 and 4.5: the elution peak for the 1 mL column elutes before that of the 3 
mL column, as the distance between the pump valve and the fraction collector is 
smaller; with both columns loaded with 10 mg of antibody per millitre of 
chromatography resin, the area under the elution profile for the 53 mm bed is 
approximately one third of that of the column 157 mm bed echoing the column 
volume ratio. Figure 4.12 shows that the bound product for a small volume column 
with reduced bed height elutes in a greater number of column volumes than the taller 
column due to the large effect of the extra-column dispersion relative to the column 
volume. Furthermore, the residence volume of the elution peak is greater for the ultra 
scale-down column. As discussed previously, with respect to the conductivity traces 
(Figure 4.4 & 4.5), this is because the extra-column volume is more significant 
relative to column volume at the smaller scale. In Figure 4.12 the areas under the 
elution curves are approximately the same (± 2%) as the eluted product 
concentration per column volume must be constant. Figure 4.12 shows that an ultra 
scale-down column cannot be used to predict the elution volume and concentration 
of the larger column simply by normalizing the elution profiles with respect to 
column volume.
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Figure 4.11. Elution profiles for the 53 mm column (■) and 157 mm column (•) . 
Error bars represent the range of duplicate measurements.
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Figure 4.12. Elution profiles for the 53 mm column (■) and 157 mm column (•) ; 
data as for Figure 4.11 but normalized using column volumes.
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The elution profile obtained with the ultra scale-down column of 5.3 cm bed height 
and column volume of 1.04 mL was corrected to make a prediction of the elution 
profile expected from a laboratory-scale column of the same diameter but increased 
bed height of 157 cm. The prediction was formulated by correcting the ultra scale- 
down elution profile, on a volume basis, to account for additional zone spreading and 
increased residence time (Figure 4.5). The correction factors were determined from 
the transition analysis data. Unlike the conductivity transition that disperses from the 
pump valve to the conductivity detector (Figure 4.3) the protein sample becomes 
more concentrated as it binds to the and then becomes more dispersed as it elutes and 
travels to the fraction collector. Although it might appear that to use data from the 
conductivity transitions would lead to over-correcting of dispersion effects on the 
protein sample, it should be considered that the elution buffer front will also become 
more disperse as it travels from the pump valve to the column inlet. This will lead to 
a more gradual drop in the pH of the column which will cause spreading of the 
proteins sample and which must also be accounted for. Although this is a 
simplification of the changing engineering environments in the chromatography 
system, the correction process offers a pragmatic approach to improving the 
predictions of elution profiles derived from ultra scale-down columns.
According to equation 4.22, the variance of the peak of the ultra scale-down column 
must be adjusted according to (cr,2oto/ *)L=15.7 /(< L / *)L=5.3 =0.31. In order to maintain 
the characteristic shape (e.g. shoulders) of the ultra scale-down column elution peak, 
the width of the peak was reduced by the ratio of the standard deviations or>/0.31 
about V*R . The height of the peak was increased by an appropriate factor in order to 
maintain the area of the peak (Figure 4.13). The resulting peak profile was narrower
147
and had a significantly higher maximum concentration than the uncorrected profile 
(Table 4.3). Further improvement in the prediction was achieved by applying a 
correction factor (f^)L=157/ ( f ^ ) i=5 3 = 0.72 to the normalized peak retention volume
as determined from Equation. 4.20, shifting the peak to earlier elution times (Figure. 
4.14). (See Appendix 2 for more details)
Since the transition analysis was performed using ionic species which diffuse 
easily into the matrix pores compared to a large protein molecule such as an 
antibody, this correction factor is likely to be an underestimation of the actual 
correction required. The final prediction, taking into account differences in both in 
residence time and degree of dispersion per column volume, gives a significantly 
better prediction of the elution profile than the uncorrected ultra scale-down data 
(Table 4.3). To use the spreading of transitions of ionic species to account for the 
dispersion of the elution buffer front upstream of the column and the protein pulse on 
and downstream of the column is a practical approach. Finding more representative 
ways to correct for the dispersion of both the pH front, which leads to product 
elution, and the protein sample as it travels from the column to the fraction collector, 
warrants further investigation. Such work may in future lead to even better 
predictions of larger-scale columns.
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Figure 4.13. MAb elution profiles obtained at different scales and after correction for 
scale effects: Elution profiles obtained with an ultra scale-down column of 5.3 cm 
bed height and 0.5 cm diameter (dotted line), and a standard, laboratory-scale 
column of 15.7 cm bed height and 0.5 cm diameter (dashed line). The data from the 
ultra scale-down column were corrected (solid line) for extra-axial dispersion effects 
arising from greater relative extra-column volume.
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Figure 4.14. MAb elution profiles obtained at different scales and after correction for 
scale effects: Elution profiles obtained with an ultra scale-down column of 5.3 cm 
bed height and 0.5 cm diameter (dotted line), and a standard, laboratory scale column 
of 15.7 cm bed height and 0.5 cm diameter (dashed line). Prediction of laboratory 
scale peak profile (solid line) after further correction of the ultra scale-down peak for 
contribution of extra-column volume to retention volume.
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Column
Column bed 
volume
(mL)
Retention
volume
(Column
Volumes)
Volume of 
elution peak 
(Column 
Volumes)
USD l 
5.3 cm x 0.5 cm 
uncorrected
1.0 2.6 2.3
USD l 
5.3 cm x 0.5 cm 
corrected
1.0 2.1 1.5
Lab scale 
15.7 cm x 0.5 cm 3.1 2.0 1.5
USD 2 
5.7 cm x 0.5 cm 
uncorrected
1.1 2.7 2.4
USD 2 
5.7 cm x 0.5 cm
corrected
1.1 2.1 1.7
Pilot scale 
14.6 cm x 40.0 cm 18,346 2.1 1.6
Table 4.3. Separation performance at different scales, based on MAb elution profiles. 
The separation performance characteristics of the ultra scale-down (USD) columns 
are given before and after correction for scale effects. USD 2 and Pilot-scale elution 
profiles are given in Figure 4.18
151
Figure 4.15 shows the effect of increasing the linear flow rate (v) on the normalized 
total dispersion (cr?otal *). The positive linear correlation over the flow rates
investigated is in accordance with the Equation 4.1 in the region where mass transfer 
kinetics of the solute through the pores of the solid phase dominate in their 
contribution to band- or transition-broadening, in contrast to the effects of molecular 
diffusion or bed tortuosity. The p-value of less than 0.05 shows that the positive 
relationship is significant; however the low R2 value indicates that, alone the linear 
flow rate variable explains only a small proportion of the variation in the normalized 
total dispersion.
The impact of increasing the linear flow rate from 61 cm/h to 150 cm/h on the 
elution profiles from the ultra scale-down column is shown in Figure 4.16. Making 
use of the linear correlation obtained from Figure 4.15, the expected elution profile 
for operation at 150 cm/h was predicted from the elution profile obtained at 61 cm/h, 
by applying a correction factor of 0.93 to reduce the variance of the peak dispersion. 
The results indicate that the use of the conductivity transition analysis method under- 
predicts the degree of elution peak broadening that occurs as a consequence of 
increasing flow rate. This may be due to the significantly different mass transfer 
characteristics used for low molecular weight ionic species of the conductivity 
measurements and the antibody macromolecules. The gradient of the least-squares 
best fit line is an inverse function of the molecular diffusivity of the analyte. As the 
low molecular weight buffer components have a high molecular diffusivity 
coefficient the increase in transition-broadening with flow rate is relatively small; 
however, as the antibody macromolecules have a significantly lower molecular 
diffusivity coefficient, broadening will be a stronger function of flow rate. Improved
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predictions are likely to be observed should correction factors be determined by 
pulse experiments, at different flow rates, using non-interacting proteins or 
antibodies under non-binding conditions However, such experiments are 
significantly less convenient to run and are not part of a normal chromatography run.
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Figure 4.15 -  Change in the normalized dispersion of the conductivity transition with 
linear flow rate. Data were obtained with the ultra scale-down column (5.3 x 0.5 cm) 
packed with rmp Protein A Sepharose 4 FF. The line is obtained from linear 
regression of data. The least-squares best fit line is defined by the 
equation, a ]otal* = 1.6xl0“5 v + 0.025, over the range of flow rates tested (R2 = 0.40 , 
p  = 0.009)
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Figure 4.16. Correction of elution profile for the change in dispersion which occurs 
with change in flow rate. MAb elution profiles obtained with USD column 2 
operated at 61 cm/h (dashed line) and 150 cm/h (dotted line). Prediction (solid line) 
of the elution profile at 150 cm/h, made by correcting the profile obtained at 61 cm/h 
by a factor of 0.93 determined using the data shown in Figure 4.15.
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4.3.4 Comparison of ultra scale-down column with pilot-scale column
Normalized conductivity transitions obtained with an ultra scale-down column 
(column volume of 1.1 mL) and with a pilot scale column (18.3 L bed volume) are 
shown in Figure 4.17. The total normalized dispersion (crfotal *) for the ultra scale-
down column was determined as 0.042 while that of the pilot-scale column was 
0.009. The use of equation 4.22 to predict the total normalized dispersion for a 
laboratory column with bed height equivalent to that of the pilot-scale column, 
would give a total normalized dispersion of 0.014, 1.6-fold greater than that obtained 
experimentally. This highlights the need to take into account discrepancies between 
the relative extra-column volumes of two chromatography systems when scaling-up, 
and suggests that characterization of the chromatography system should be done 
directly on the relevant large-scale system. Figure 4.18 shows the effect of applying 
a correction factor to reduce the dispersion of the elution profile from the ultra scale- 
down column by 0.21, according to the ratio of the normalized total dispersion 
acquired from the transition analysis at the two scales (Figure 4.17). Further 
correction of the ultra scale-down column elution profile for the effect of the extra­
column volume on retention volume was made, based on the transition data, 
reducing the retention volume by a factor of 0.74 (Figure 4.19).
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Figure 4.17. Conductivity transitions obtained from an ultra scale-down column 
(dashed line) (5.7 cm height, 0.5 cm diameter, 1.12 mL volume) and a pilot scale 
column (solid line) (14.6 cm height, 40.0 cm diameter, 18.3 L bed volume). Both 
columns were packed with Protein A sepharose 4 FF. The normalized total 
dispersion variance (<J?otal *) of the transition are 0.042 and 0.009, for the ultra scale-
down and pilot columns, respectively. A: normalized conductivity data; B: the first 
derivative of the conductivity data with respect to column volumes, giving an insight 
into the maximum rate of change and dispersion associated with each curve.
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Figure 4.18. Prediction of pilot-scale antibody elution peak from elution data 
obtained with an ultra scale-down column. Elution profiles obtained with ultra scale- 
down column of 1.1 mL bed volume (5.7 cm height, 0.5 cm diameter) (dotted line), 
and a pilot-scale column of 18.3 L bed volume (14.6 cm height, 40.0 cm diameter) 
(dashed line). The ultra scale-down elution profile was corrected for dispersion 
effects to give prediction of pilot scale peak (solid line).
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Figure 4.19. Prediction of pilot-scale antibody elution peak from elution data 
obtained with an ultra scale-down column. Elution profiles obtained with ultra scale- 
down column of 1.1 mL bed volume (5.7 cm height, 0.5 cm diameter) (dotted line), 
and a pilot-scale column of 18.3 L bed volume (14.6 cm height, 40.0 cm diameter) 
(dashed line). Ultra scale-down elution profile corrected for extra-column volume 
effects on residence time (solid line).
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4.4 Conclusions
It has been shown, in this chapter, that it is possible to predict the elution profile of a 
monoclonal antibody from a pilot scale protein A chromatography column (18 L bed 
volume) based on data obtained with an ultra scale-down column (1 mL bed 
volume). Correction of peak profiles, to account for increased axial dispersion and 
solute retention times due to higher relative extra-column volumes in small columns, 
is necessary for accurate predictions. Conductivity transition tests can be used on 
columns at both scales to determine the necessary correction factors. If these 
corrections are not applied, lower maximum and average pooled product 
concentrations could be predicted for the elution peak at large-scale, with unexpected 
and undesirable consequences in large-scale operation, such as product instability at 
high concentrations.
The concern when using columns with narrow diameters such as the ultra 
scale-down column described in this chapter, is that the bed resin particles are 
supported by the column wall and therefore the bed does not undergo compression to 
the same extent as at the large-scale. For this reason, high flow rates achieved in a 
column with a narrow diameter can often not be used in a wide diameter column, 
because the hydrodynamic pressure drop across the bed would be excessively large 
and lead to equipment failure. A method by which flow rates proposed for the large- 
scale can be assessed prior to operation of the large-scale column is described in the 
next chapter.
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Chapter 5 -  The construction and use of a semi-empirical model for predicting 
scale-dependent chromatography bed compression and its use with ultra scale- 
down chromatography. 
5.1 Introduction
Determining optimum elution flow rates, to maximize productivity without 
exceeding elution volume constraints (imposed by the capacity of the elution fraction 
collection vessel) is an important part of chromatography process development. In 
Chapter 4 the use of ultra scale-down chromatography techniques to predict the 
elution profiles from large scale chromatography columns over a range of flow rates 
was demonstrated. Operating flow rates determined at the laboratory-scale are 
frequently unachievable at the large scale due to the compressible nature of the 
highly porous agarose resins commonly used in preparative chromatography media. 
Increases in column diameter and the resultant loss in wall support lead to both 
greater resin compression and hydrodynamic pressure drops across the bed.
To make use of the ultra scale-down chromatography technique for 
predicting elution profiles, a method for identifying which elution flow rates are 
achievable at the large-scale is required. The work described in this chapter focuses 
on the use of a published semi-empirical model that can be used in conjunction with 
ultra scale-down chromatography techniques, to ensure that operating parameters 
determined with the small-scale column will be achievable at the large scale.
The compression of packed beds is affected by friction between the wall and 
the bed particles and internal friction between particles in the bed. In the past, 
models to predict bed compression have been based on force balances, while
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accounting for the varying contributions of friction; however, the number of 
variables to be defined makes their application complicated (Colby et al., 1996; 
Soriano et al., 1997). Empirically derived models exist and are easier to use; 
however, many empirical models cannot predict the effect of decreasing bed height 
with flow-induced compression (Mohammad et al., 1992). The objective of this 
study was to experimentally determine the parameters required for the use of an 
empirical model to predict the pressure drop in compressible packed beds, at varying 
scales. The research uses a semi-empirical method to predict decreasing bed height 
with compression, which is less complex than non-empirical solutions (Stickel and 
Fotopoulos, 2001).
The parameters of linear flow velocity, pressure drop and bed height are co­
dependent. For the purpose of constructing this model it was assumed that linear 
flow velocity is an independent variable. Increases in linear flow velocity lead to an 
increase in the fluid drag on the packed particles and cause bed compression (X). Bed 
compression is defined by the equations:
where Vc is the packed bed volume at bed height L, Vco is the gravity-settled bed 
volume and La is the gravity-settled bed height. Bed compression must lead to a 
decrease in interstitial bed porosity (e) and reduced permeability, as defined by the 
following relationship (Stickel and Fotopoulos, 2001):
V - V
 £
Vco
Equation 5.1
e =
1 - J L
Equation 5.2
162
where 80 is the gravity settled bed porosity. The observed increase in pressure drop is 
a result of both increased fluid velocity and reduced bed permeability. At a critical 
flow velocity (ucri), an increase in pump speed leads to an increase in bed 
compression but no increase in linear flow velocity. Hence, the critical bed 
compression (X cri) is defined by the formula:
Xcrj = —— Equat i on 5.3
L0
where Lcri is the bed height at the critical point. Increases in pressure drop beyond the 
critical point are as a result of decreasing permeability alone, as the linear flow 
velocity does not increase. It has been observed that bed compression plotted as a 
function of linear flow velocity shows an approximately linear relationship, 
described by the following equation (Stickel and Fotopoulos, 2001):
Equation 5.4
X ■ ucri cri
It has also been observed that X cri does not vary significantly with aspect ratio, 
implying that this parameter is material-specific and unaffected by wall support. X cri, 
therefore, provides an indication of the magnitude of change in bed height that a 
packed bed undergoes as the critical velocity is approached (Stickel & Fotopoulos, 
2001).
5.1.1. Correlation between column aspect ratio and medium compressibility: It has 
been previously shown (Stickel & Fotopoulos, 2001) that the critical velocity can be 
correlated with bed height and column diameter by plotting the term ucriL0 as a
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function of the column aspect ratio (LJD ) and that the relationship is linear (Stickel 
& Fotopoulos, 2001). This permits the use of the empirical correlation:
( L \
U criL o =  m + b Equation 5.5
k D j
where m and b are empirical constants, determined by linear regression. The 
empirical constant b is the value of ucriL0 for an infinite diameter column and 
provides, therefore, a numerical indication of the compressibility of the medium 
under a given set of operating conditions. The slope m indicates the changing wall 
support with scale.
5.1.2 Modeling Pressure-Flow Profiles. The Blake-Kozeny equation can be used to 
describe the pressure drop across packed beds of rigid particles under laminar flow 
(Geankoplis, 1993):
K~ (1 V
AP = f j —- - — y ~ L .u Equation 5.6
d p 6
where p is fluid viscosity, dp is the particle diameter and Ko is an empirical constant. 
The model assumes both constant bed height and porosity which is not the case for 
systems involving compressible media. The use of Blake-Kozeny equation is, 
however, justified as bed height and porosity can be correlated to the linear flow 
velocity. Of the material properties, particle diameter and critical bed compression 
were found experimentally whilst porosity values were obtained from the literature 
(Stickel & Fotopoulos, 2001).
5.1.3. Calculation Methodology. For a given column geometry the critical velocity, 
Ucri, is determined using Equation 5.5. During packing at any given linear flow rate 
the bed compression can be calculated using Equation 5.4. Subsequently, this value
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can be used in Equations 5.1 and 5. 2 to determine values for bed height and bed 
porosity at that flow velocity. These values, along with the structural properties of 
the media and the viscosity of the liquid phase, can be used in the Blake-Kozeny 
equation (equation 5.6) to predict the pressure drop for a given linear flow velocity. 
A predicted pressure-flow curve can be generated by repeating the procedure over a 
range of linear flow velocities, until the critical velocity is reached, beyond which 
the empirical correlation for compression as a function of fluid velocity is no longer 
valid.
5.2 Materials and Methods
5.2.1. Equipment. A transparent laboratory-scale column (model XK26, Amersham 
Biosciences, Piscataway, NJ) with adjustable length and an inner column diameter of 
26 mm, was used. Analogue pressure gauges mounted on the column inlet and outlet, 
were used to measure pressure drops across the bed. Either (i) the peristaltic pump 
and pulse dampener of an AKTA Prime system were used to pump buffer through 
the column in order to achieve stable pressure and flow rate readings or (ii) 
compressed air was used to overpressure buffer from a 10 L pressure canister 
through the column. A 25 mL measuring cylinder and a stop watch were used to 
measure column effluent flow rates and a ruler used to measure packed bed heights 
(Figure 5.1).
A particle size analyzer (Mastersizer, Malvern Instruments, Southborough, 
MA) was used to verify the particle size distribution of the chromatography media.
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5.2.2. Chromatography Media. The resin used in this study was rmp Protein A 
Sepharose 4 Fast Flow (Amersham Biosciences, Sweden).
5.2.3. Procedures. 20% ethanol, 50 mM glycine-glycinate, 250 mM sodium chloride, 
pH 8.0 and 6 M guanidine hydrogen chloride were used as mobile phases and 
recycled through the column during packing and operation. In each case the buffers 
were allowed to equilibrate to room temperature (22 °C) prior to the commencement 
of experiments. A pressure-flow rate profile was generated for the empty column and 
associated equipment prior to packing (Figure 5.2). This curve was subsequently 
used to subtract equipment pressure drop from the total pressure drop to determine 
the pressure drop across the packed bed alone. All pressure-flow profiles shown have 
been corrected for the equipment pressure drop.
Prior to packing, the slurry concentration, in terms of gravity-settled medium, 
was determined by centrifuging 10 mL samples of slurry for 5 minutes at 4000rpm in 
an ALC centrifuge PK120 with soft acceleration and deceleration.
For each experiment, a measured volume of slurry was poured into the 
column and allowed to settle under gravity. To generate a packing pressure-flow 
curve, the top adapter was left fully raised and an initial pressure drop of less than 4 
x 104 Pa was maintained across the column for a minimum of 0.5 h to allow the flow 
rate and bed height to equilibrate, before inlet pressure, outlet pressure, flow rate and 
bed height were recorded. The pump speed or air pressure (as appropriate) was then 
increased to achieve an incrementally greater pressure drop and a further 0.5 h 
allowed before measurements were retaken. This process was repeated until a very 
large change in pressure resulted from a small change in pump speed or until 
consistent flow rates were observed despite an incremental increase in air pressure to
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the pressure canister. A summary of all columns discussed in this chapter is given in 
Table 5.1.
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Figure 5.1. Schematic diagram of the experimental set-up for generating the 
pressure-flow curves.
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Figure 5.2. Equipment pressure-flow profiles for four different initial bed heights. 
Column diameter is 26 mm. Packing buffers are indicated on the figure annotation. 
(■) 80 mm bed height; ( • )  150 mm bed height; (A) 300 mm bed height; (▼) 450 
mm bed height.
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Bed height 
_ ( c m ) ------
Diameter
(cm)
Volume
(mL)
Aspect
Ratio Use
8 2.6 42.5 3.1 Emperical constant determination
15 2.6 79.6 5.8 Emperical constant determination
30 2.6 159.3 11.5 Emperical constant determination
45 2.6 238.9 17.3 Emperical constant determination
5 0.5 1.0 10.0 USD - model prediction
15 40 18,849.6 0.4 Pilot - model prediction
15 200 471,238.9 0.1 Production - model predition
Table 5.1. Summary of columns used in this chapter
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5.3 Results
Figures 5.3, 5.4 and 5.5 show pressure-flow profiles for the three different liquid 
phases for packed beds of the same diameter but different heights. The non-linear 
profiles are characteristic of compressible media. The linear flow velocities were 
increased beyond the upper limits shown; however, this led to increases in cross-bed 
pressure drop above 4.2 x 105 Pa at which point the matrix permanently deforms. As 
the pressure across the bed did not reach equilibrium, a pressure reading could not be 
taken and hence the data are not shown. The linear flow velocity at which the slope 
of the curve becomes infinite is defined as the critical velocity and is the highest 
achievable steady-state flow velocity for a packed bed under a given set of 
conditions. Lower critical velocities imply greater compression and the data confirm 
observations that shallow beds are more stable than tall beds (Soriano et al., 1997).
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Figure 5.3. Pressure-flow profiles for four different initial bed heights. Column 
diameter is 26 mm. Packing buffer is 20% ethanol at 22°C. (■) 80 mm bed height; 
( • )  147 mm bed height; (▲) 306 mm bed height; (▼) 444 mm bed height.
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Figure 5.4. Pressure-flow profiles for four different initial bed heights. Column 
diameter is 26 mm. Packing buffer is 50 mM glycine-glycinate, 250mM sodium 
chloride, pH 8.0 at 22°C. (■) 79 mm bed height; ( • )  147 mm bed height; (A) 290 
mm bed height; (▼) 455 mm bed height.
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Figure 5.5. Pressure-flow profiles for four different initial bed heights. Column 
diameter is 26 mm. Packing buffer is 6M guanidine hydrogen chloride at 22°C. (■) 
78 mm bed height; ( • )  150 mm bed height; (A) 305 mm bed height; (▼) 445mm 
bed height.
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The variations in critical velocities over the range of bed heights studied for each of 
the liquid phases can be seen in Figure 5.6. The critical velocities for 50 mM 
glycine-glycinate, 250 mM sodium chloride, pH 8.0, at different bed heights, are 
greater than those for both 6M guanidine hydrogen chloride and 20% ethanol 
primarily due to the lower viscosity of the glycine-glycinate, sodium chloride (see 
Table 5.2). 20 % ethanol has a higher viscosity than the 6M Guanidine-HCl yet the 
model predicts higher critical velocities at the same flow rate. The difference in the 
viscosities of the two fluids is not sufficiently great to be detected by the accuracy of 
the analogue pressure gauges using only the single measurements taken during these 
experiments. Figure 5.6 demonstrates that care must be taken when using columns 
with reduced bed heights for developing purification processes as taller columns 
used in manufacturing cannot be operated at similarly high flow rates.
The method of determining the empirical constants for the model by linear 
regression is illustrated in Figure 5.7. The empirical constant b shown in Table 5.2 is 
the value of uChL0 for an infinite diameter column; hence, large values indicate that 
the mobile phase will compress the chromatography bed to a lesser extent. It may be 
expected that as the viscosity increases, ucriL0 decreases due to viscous drag. It 
should be noted that all experiments were performed with columns of the same 
diameter and that the column aspect ratio (Lo/D) was varied by changing the bed 
height, Lo. However, the slope m implies changing wall support with scale and the 
shallow gradient suggests that the shift in pressure-flow profiles between columns 
with different diameters may not be particularly pronounced. Table 5.2 also shows 
the R2 values for the least squares best fit line. All values are greater than 0.99
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indicating that almost all the variation in the independent variable is described by the 
regression model.
Figure 5.8 shows that the model predicts different bed structures for the ultra scale- 
down and large-scale column. The model used for these predictions was constructed 
using the empirical constants determined for 50 mM glycine-glycinate, 250 mM 
sodium chloride. The figure shows that both large-scale columns are more 
compressed at the same linear flow rates than the ultra scale-down column and that 
the bed void fractions are lower. This is a consequence of the different bed heights 
and reduced wall support for the matrix. It may be imagined that such differences in 
bed structure would lead to differences in column performance between the ultra- 
and the large-scales. For example, if the resin particles are more densely packed in 
the large-scale columns, it would seem likely that the capacity of the column per unit 
volume would be higher as more ligand per unit volume must be present. A reduced 
column void fraction might also imply greater interstitial linear velocities and, in 
turn, altered mass transfer characteristics in chromatography beds at the large-scale. 
Determining if such changes in bed structure with scale affect column performance 
is a subject for future investigations. The results of such investigations may even 
allow for a greater refinement of the process for correcting data from the ultra-scale 
to predict performance at the large-scale.
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Figure 5.6. Critical linear velocities for four different bed heights in a 26 mm 
diameter column at 22 °C, for three different buffers, (■ ) 20% ethanol, ( • )  50 mM 
glycine-glycinate, 250mM sodium chloride, pH 8.0, (A ) 6 M guanidine hydrogen 
chloride.
Medium
Mobile
Phase
viscosity 
(cP) 
at 23 °C
m
(cm2/h)
B
(cm2/h)
R2
Sepharose
4FF
20% ethanol 2.24 500 2050 0.99
Sepharose
4FF
50mM glycine- 
glycinate, 250mM 
sodium chloride, 
pH 8.0
l.40 770 3320 0.99
Sepharose
4FF
6M guanidine 
hydrogen chloride
2.02 383 2350 0.99
Table 5.2 Mobile phase viscosity values and empirical constants for critical velocity 
correlation. The slope, m , intercept, b, and coefficient of determination, R , refer to 
the linear regressions shown in Figure 5.6.
Medium dp (pm) £o A,Cri
Sepharose 4FF 96 0.41 0.21
Table 5.3. Structural properties of Sepharose 4FF
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Figure 5.7. Experimental data for determining the empirical constants m and b (see 
Table 5.2) for Sepharose 4FF matrix at 22 °C with three different buffers, (■ ) 20% 
ethanol, ( • )  50 mM glycine-glycinate, 250 mM sodium chloride, pH 8.0, (A ) 6 M 
guanidine hydrogen chloride according to equation 5.5.
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Figure 5.8. The effect of changing scale on the structure of the chromatography bed 
packed with Sepharose 4FF. Model predictions of the degree of bed compression 
over a range of linear flow rates for; (■) the ultra scale-down column (0.5 x 5 cm); 
( • )  400 mm diameter pilot column; (▲) 2000 mm diameter manufacturing scale 
column. The bed voidage as a function of flow rate is given by; (□) ultra scale-down 
column; (O) 400 mm diameter pilot column; (A) 2000 mm diameter manufacturing 
scale column. Both pilot and manufacturing columns have a bed height of 15 cm. 
The model used to generate the predictions was constructed using the empirical 
constants m and b determined for 50mM glycine-glycinate, 250mM sodium chloride 
(Table 5.2.)
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Model predictions for bed heights and cross column pressure drops over a range of 
linear flow rates, for the ultra scale-down column, the 400 mm diameter pilot column 
and a 2000 mm diameter manufacturing scale column are shown in Figure 5.9. 
Greater cross-column pressure drops are predicted for the large-scale columns due in 
part to the taller beds but also significantly from the loss in wall support for the bed 
as the diameter is increased. It might have been expected that the influence of 
decreasing wall support would be negligible above a diameter of 400 mm and 
therefore it is of interest that the model predicts a slightly lower pressure-flow profile 
and higher bed height for the pilot than for the industrial-column, at equivalent linear 
flow rates. It is also noteworthy that the decrease in bed height with increasing linear 
flow rate in the two large scale columns is greater than that of the ultra scale-down 
column. The results show the potential danger of using an ultra scale-down column 
for the development of large scale processes. It is evident from the predictions that 
an ultra scale-down column can be operated at significantly higher flow rates than 
either the pilot- or manufacturing-scale columns. The predictions show that an ultra 
scale-down column can be operated at linear flow rates beyond 350 cm h '1 with no 
significant increase in cross-column pressure drop or decrease in bed height. Both 
the pilot and manufacturing columns would be inoperable above a linear flow rate of 
250 cm h 1 because the pressure drops across the beds would be too great and would 
lead to equipment failure. This would not have been predicted by the ultra scale- 
down column highlighting the need for a ‘toolbox’ of methodologies and equipment 
including mathematical models for the development of processes at the ultra-scale.
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Figure 5.9. The impact of increasing scale, from the ultra scale-down to the pilot- 
scale and industrial-scale, on the operability of chromatography columns packed 
with Sepharose 4FF. Model predictions of bed heights over a range of linear flow 
rates for (■) the ultra scale-down column; ( • )  400 mm diameter pilot column; (▲) 
2000 mm diameter manufacturing-scale column; and the cross-bed pressure drops 
for (□) the ultra scale-down column; (O) 400 mm diameter pilot column; (A) 2000 
mm diameter manufacturing scale column, over the same linear flow rates. The 
model used to generate the predictions was constructed using the empirical constants 
m and b determined for 50mM glycine-glycinate, 250mM sodium chloride (Table 
5.2).
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5.4 Conclusions
Relationships have been determined that allow pressure drops to be predicted in 
columns of different heights and diameters packed with Sepharose 4FF. The model 
has been used with three different chromatography buffers. At any given flow rate 
the degree of bed compression, bed height and bed porosity can be predicted. 
Verification of the model is provided in the literature and so has not been included in 
this study (Stickel & Fotopoulos, 2001).
Results from the model show that the bed structure of ultra scale-down columns and 
large-scale columns will be different at equivalent linear flow rates. Structural 
differences may lead to differences in separation performance and will require 
further investigation. The results of studies on the effects of bed compression on 
column performance may further enhance our ability to accurately predict 
chromatographic behaviour at the large-scale from data derived from the ultra-scale.
Significantly, it has been shown that high flow rates accessible at the ultra-scale can 
not be applied at the large-scale due to matrix compression caused by the loss of wall 
support at increased column diameters. The model generated by this work is a useful 
tool that must be used alongside the ultra scale-down column to allow the 
development of operable chromatography processes capable of delivering the 
required performance.
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Chapter 6 -Discussion
6.1. Conclusions
Laboratory-scale experiments are likely to play an important role in the development 
of large-scale bioprocesses. Conventional scaling rules (Doran, 1994), such as 
increasing chromatography column diameter while maintaining bed height and linear 
flow rate, impose a limit both on the amount of data that can be collected (and, hence 
on the degree to which a process can be optimized in the limited time available) and 
on the minimum amount of material required to conduct such studies. Novel 
techniques allowing more rapid process development with small volumes of process 
material are required. To this aim the following have been reported in this thesis,
• mimicking the clarification performance of continuous, pilot-scale 
centrifuges using an ultra scale-down technique requiring a few hundred 
millilitres of process material. Results showed that the performance of both a 
soft- and normal-feed centrifuge could be predicted by adjusting the 
conditions within a rotating-disc device designed to mimic the hydrodynamic 
environment of the continuous centrifuge feed-zone.
• demonstration of the comparability between the large- and ultra scale-down 
centrifuge supernatant and product.
• development of a centrifugation, windows of operation visualisation tool to 
allow process design decisions to be made readily from ultra scale-down 
data.
184
• verification of the ultra scale-down centrifugation technology by comparison 
of predictions with the performance of a manufacturing-scale, disc-stack 
centrifuge, used to harvest a 20,000 litre cell culture bioreactor.
• development of a technique to adjust elution profiles for extra-column zone 
broadening when using scaled-down columns with reduced bed heights.
• addition of an existing model to the scaled-down chromatography toolbox to 
facilitate their scale-up and suggest future investigations to improve 
predictions.
6.2 Discussion and recommendations for future work
6.2.1. Ultra scale-down centrifugation
In this thesis the ultra scale-down centrifuge methodology in which the rotating-disc 
device mimics hydrodynamic conditions in the feed zone of the large-scale 
centrifuge has been successfully applied to the development of centrifugation 
processes, for the clarification of mammalian cells from two therapeutic monoclonal 
antibody processes, at two different scales (Chapters 2 & 3). On the basis of this 
success it is worth considering issues governing the uptake of the technology. The 
design of the rotating-disc device is now at the point where it can be developed 
beyond a prototype. For use in a commercial environment a reliable and reproducible 
method for charging the chamber with liquid, while ensuring the exclusion of air is 
required; robust sealing of the chamber at the point at the impeller shaft bearing is 
also essential. In addition, software would be needed for the relatively complex 
calculations required to determine the operating conditions of the laboratory
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centrifuge and the rotating-disc device. More trials would be required to help verify 
that the technique can be used to predict accurately centrifuge performance with 
different cell lines and cell culture processes.
6.2.1.1. Future uses of ultra scale-down centrifuge technology
The biopharmaceutical industry seeks to invest in research aimed at 
increasing cell culture product titres, to give increasingly productive manufacturing 
processes. Ultra scale-down methods can be used to evaluate the effect of associated 
cell culture changes on product recovery. Although the economic value of using ultra 
scale-down methods is difficult to determine and outside the scope of this thesis, an 
ultra scale-down centrifuge tool can be utilized to yield a real a benefit. For example, 
shortening the duration of cell culture by early harvesting could be effective if 
product quality deteriorates towards the end of a fermentation. Ultra scale-down 
centrifugation would be ideal for assessing the impact of this change on clarification 
processes, and without the need for expensive large-scale cell culture fermentations 
of varying dilutions; samples could be harvested from a single fermentation at 
different times and run in the scaled-down centrifuge.
In the time between the centrifuge experiments reported here which were 
carried out on the NSO cell line 6A1( 100)3 and the completion of this thesis the 
proportion of processes utilizing NSO cell lines has decreased and the proportion 
using CHO cell lines has increased. CHO fermentations typically maintain and are 
harvested at higher cell viabilities than NSO fermentations. Although the data 
presented in Table 2.1 showed that there was no significant shear-related release of 
impurities from NSO cells this could be due to the low cell viability at the point of
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harvest, which would have lead to significant impurity release prior to harvest. This 
is unlikely to apply with a CHO cell line harvested at higher cell viability where 
impurity release during harvesting may be much more significant. Testing this 
hypothesis with the ultra scale-down centrifuge tool would be of great industrial 
interest as selection of low-shear harvesting operations could relieve downstream 
bottlenecks caused by increased product titres. A reduction in cellular impurities 
entering purification processes could allow the use of high-throughput (although 
currently low-capacity) alternatives to chromatography, such as membrane 
adsorbers.
Increasing cell culture titres combined with successful large-scale cell 
cultivation are creating urgent development targets downstream of the bioreactor to 
facilitate capture and purification of increasingly large masses of product. 
Manufacturers are actively seeking novel alternatives to chromatographic 
purification methods to alleviate mammalian cell protein purification bottlenecks. 
Operations based on precipitation and crystallization, for example, may require 
solid-liquid separations that could be performed using centrifuges. The ultra-scale 
centrifuge protocols, combined with operating windows, would provide an ideal 
technique for evaluating the integration of such new steps and would allow 
equipment specification at an early stage in process development. The shear 
sensitivity of solid particles could be determined at the bench-scale to allow 
identification of the most suitable separation technology. If  the decision to use a 
centrifugal separator at the large-scale was taken, then the size and flow rates could 
be specified long before pilot-scale studies commenced. Contract manufacturers may 
find that new separation techniques are less generic than existing technologies;
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process development at the ultra-scale could be routinely used to specify product- 
specific processes.
Further research is required to assess the impact of hydrodynamic forces on 
glycosylated proteins (Qvist et al., 2006). Although the results presented in this 
thesis indicate no gross effects on the antibody studied (Section 2.3.3.), more subtle 
alterations to the molecular structure may have occurred requiring investigated using 
advance analytical techniques such as mass spectroscopy. Proteins other than 
antibodies such as hormones may have complex multi-subunit structures making 
them more fragile and sensitive to shear; product comparability studies need to be 
carried out for each new product.
6.2.1.2. Microscale centrifugation
Ultra scale-down centrifugation, using a few hundred milliliters of material, need not 
be the smallest scale for centrifuge process development. Laboratory centrifuges 
such as the IEC Centra manufactured by Thermo Electron are available that hold 
microwell plates. Preliminary studies, conducted during the course of this research, 
though not presented as part of the thesis, showed that 96-well plates with a capacity 
of 350 pL of fluid per well could be used to clarify cell culture supernatant (Tylka,
2003). Different equivalent flow rates could be achieved by varying the volume of 
process fluid in the well; dimishing clarification performance was observed with 
increasing equivalent flow rate. The method was significantly quicker than the ultra 
scale-down centrifuge method, because the particle settling distance was very small, 
and in particular, because many equivalent flow rates could be studied in a single 
centrifuge. Further, the micro-well centrifugation technique could be automated
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using liquid-handling robots: microwell plates could be charged with process 
material, centrifuged and supernatant withdrawn and loaded into a second microwell 
plate for optical density determination at the appropriate wavelength using, the 
liquid-handling system. The use of liquid-handling systems should lead to a highly 
reproducible technique, which is of particular importance when dealing with 
microlitre volumes of material. Initial trials of this technology showed that the 
clarification results from the microwell plate and the ultra scale-down centrifuge 
were similar, although the microwell plate technique consistently failed to clarify the 
cell culture broth to the same extent as the ultra scale-down protocol at the same 
equivalent flow rates(Tylka, 2003). This discrepancy requires further investigation.
6.2.2. Ultra scale-down chromatography
Considerable resources are allocated to the development of chromatographic 
processes in the biopharmaceutical industry due to their complex nature. A large 
number of factors need to be considered, including appropriate resin selection, buffer 
composition, flow rates and bed height. The pressure to progress to clinical trials in 
the shortest time possible permits only limited process optimization. This can lead to 
inefficiencies in manufacturing product batches at the large-scale. Rapid techniques, 
requiring very small volumes of process material but allowing reliable prediction of 
the performance of large-scale columns would be of considerable use. Such 
techniques would allow testing of a greater number of process alternatives than is 
currently possible for short development projects. Despite being frequently 
overlooked in published literature, intermediate product volumes are also an 
important and frequently poorly predicted variable. For example, variations in
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elution volumes affect product concentrations entering subsequent operations and 
can contribute to product instability. The presence of large intermediate product 
volumes leads to inefficient use of a manufacturing facility; the ability to predict 
these volumes would allow operating managers to efficiently plan the processing of 
such volumes.
6.2.2.1. Applicability of ultra scale-down column to anion- and cation-exchange 
chromatography development.
Elution volumes from affinity chromatography columns were studied in this 
thesis (Chapter 4). Both anion- and cation-exchange columns are also frequently 
utilized in the manufacture of therapeutic recombinant proteins such as monoclonal 
antibodies. Determining the applicability of the method of elution volume correction 
would be to these two methods of chromatography is of interest and could be 
investigated in future. In monoclonal antibody processing anion-exchange 
chromatography is typically operated as an impurity capture step, during which the 
product does not bind to the resin. Determining the elution volume of the product as 
it flows through the column would be of interest. During a well-operated anion- 
exchange step, the product and captured impurities should be separated within the 
chromatography system by a large volume of wash buffer, as occurs during affinity 
chromatography. Hence, the additional zone-spreading experienced at the ultra-scale 
should have little impact on the product purity achieved by this step and, thus, 
loading and wash buffer conditions specified at the ultra scale-down should be 
applicable to larger-scale columns.
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Unfortunately the opposite is true during cation-exchange chromatography 
when the accurate prediction of elution volumes is most important. The purpose of 
the cation exchange step is to separate monomer product from aggregated product. 
The similarities between these molecules means that they frequently have similar 
elution residence times and overlapping elution profiles (Bonnerjea, 2006). 
Development of a robust cation-exchange step typically requires the identification of 
a cation concentration that will separate the monomer from the impurities without 
causing the product to elute in an unacceptably large volume. As material available 
for such studies is often especially valuable and limited, due to the number of steps 
required to generate it, the use of the ultra scale-down column for such studies would 
be of great use. At the production scale, more highly optimized steps are likely to 
lead to large reductions in the cost of goods, as small improvements in yield are 
significant at this stage when the product has had considerable value added to it. 
Although the ultra scale-down column would be a very valuable tool in the 
development of cation-exchange chromatography steps, similarities between the 
retention times of the product and impurity would require the additional complexity 
of correcting for the effect of extra-column mixing on product purity to be 
considered.
6.2.2.2. Dynamic binding capacity determination using ultra scale-down 
chromatography methods
The dynamic binding capacity of a resin under a given set of conditions is an 
important design variable. Determining the capacity of the resin for the product 
using an ultra scale-down column would be of great value as it would minimize the
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amount of material required for such a study. It is likely, however, that the dynamic 
binding capacity of the small scale column would over predict the capacity of a large 
scale column because of the way in which bound product is distributed on a loaded 
column. At the column inlet the concentration of the product in the mobile phase is 
at a maximum and hence there exists the maximum concentration gradient between 
that and the stationary phase that will drive the diffusion of product molecules 
through the stagnant layer of fluid that surrounds resin particles and onto the resin. 
As the fluid flows down through the column the concentration of the product in the 
mobile phase and hence the concentration gradient between the mobile and 
stationary phases decreases due to binding of product to resin close to the inlet. For 
this reason matrix close to the outlet is less efficiently utilized than the resin at the 
top of the column. The total dynamic binding capacity of a column with a reduced 
bed height will be greater than that of a large-scale column because it mimics the 
performance of the top of the large scale column only.
6.2.2.3. Micro-scale chromatography
The use of ultra scale-down columns would allow a greater number of 
process alternatives to be tested using the same amount of material. However, the 
total number of variables is extremely large and a full screen of these variables 
would be resource intensive. As has been proposed for the development of 
centrifugation processes (Section 6.2.1.2.) the use of microwell plate technology 
could allow the screening of even more variables in a shorter space of time than 
could be achieved at the ultra-scale. One method of achieving a screen of 
chromatography conditions in a microwell plate format would be to use 100 pL
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volumes of resin in a microfilter plate which can be equilibrated, loaded and eluted 
using a vacuum manifold capable of sucking the appropriate solution (previously 
loaded into the well) through the resin bed and discharging it into a collection plate. 
Using this technique many different combinations of resins and buffers could be 
tested, to determine those most useful for given purposes. For evaluation of elution 
buffers resin could be pre-equilibrated and loaded with product prior to being 
aliquoted into wells to maximize experimental throughput. Up to 96 different process 
combinations could be studied on a single plate and the process could be readily 
automated using liquid-handling robots. It is unlikely that either the ultra scale-down 
method (Chapter 4) or the proposed microwell method used in isolation would form 
an entire strategy for developing chromatography processes, but that together, along 
with the appropriate mathematical models they would form a “toolbox” for the 
complete characterization of separation processes. It should, however, be 
remembered that this type of high-throughput chromatography development work 
would generate large numbers of samples for analysis. It is easy to conceive that 
sample analysis could then become the limiting factor. Although analytical capacity 
can be increased with few technological obstacles it would add significantly to the 
cost of the process development. Increasing analytical throughput to support 
bioprocess development is a major technological challenge for scientists working in 
that field.
6.2.3. Whole bioprocess scale-down
This thesis has focused on two unit operations used in the purification of 
monoclonal antibodies; however, ultra scale-down techniques are required for every
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unit operation in the process, including normal flow filters and tangential flow 
membranes. Once this has been achieved then material from scale-down of one unit 
operation can be fed into subsequent process steps for the development of entire 
bioprocesses. Considerable progress has been made in recent years in the use of 
scale-down bioreactors for the development of cell culture processes (De Jesus et al.
2004). Such miniature bioreactors will not yield sufficient volume of material or 
mass of product to permit downstream process development using conventional 
techniques. Only ultra-scale and micro-scale process development methods can 
generate useful data with limited process material. Furthermore, by linking ultra 
scale-down operations together it will be possible to investigate the complex 
interactions between processing steps. For example, the relationships between the 
clarifying performance of operations such as centrifuges and filters and the degree of 
fouling of purification operations such as packed bed chromatography columns or 
the generation of product aggregates during cell cultivation and the removal of the 
aggregates by cation-exchange chromatography. Currently, performing experiments 
to investigate such interactions would be too expensive even at pilot or laboratory- 
scales; however, they could be performed rapidly and inexpensively at an ultra- or 
micro-scale. The ability to run entire bioprocess at these scales fully representative 
of the large-scale, could be included into process validation protocols during which 
process control limits are set and tested. Availability of scale-down techniques would 
allow simultaneous testing of a large combination of process limits to ensure safe 
and effective operation.
The development and operation of manufacturing process for the production 
of safe recombinant protein therapeutics continues to require a combination of skill 
and experience, even though this class of pharmaceutical has been approved for
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marketing for twenty years (eg. Muromonab-CD3 for transplant rejection) (Guru, 
2002). Prices of this category of drug will be driven down by the inevitable and 
imminent loss of patent protection for currently marketed products and the 
introduction of generic biopharmaceuticals such as has occurred outside the USA 
with generic forms of erythropoietin (ie Eprex (Johnson & Johnson), NeoRecorman. 
(Roche) and Dynepo (Shire)). Manufacturers of products under patent protection 
need to maximize their monopoly on the market by getting products to the market as 
rapidly as possible, thus reducing costs and prices and minimizing the impact of 
generic products when the monopoly comes to an end. Increased competition will 
force manufacturers to ensure that their processes operate as efficiently as possible; 
enabling technology will be even more essential than at the current time. There is 
every reason to believe that empirical approaches to process development, providing 
industrially applicable data with minimal amounts of process material, will 
significantly contribute to improvements in process efficiencies.
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A ppendix 1 - Transition analysis sam ple calculations
Columns 1 & 2 of Table A. 1.1. show data from the conductivity transition paired 
with the respective volume data. The conductivity data is normalized using the 
maximum and minimum response data given in Table A. 1.2.and Equation A. 1.1.,
value -  min imum response _ . , ,
R =  :  ---------  Equation A. 1.1
max imum -  min imum response
1 2 3 4 5
R esponse
(Conductivity)
(mS.cm'1)
Volume
V
(mL)
Normalised
Conductivity
R
(-)
dR/dV Moving average  dR/dV
17.701 4.586
s s ^ s
0.692 2.190
17.476 4.590 0.683 2.270 2.068
17.303 4.594 0.676 1.746 1.729
17.187 4.598 0.671 1.170 1.366
17.07 4.602 0.667 1.181 1.181
16.952 4.606 0.662 1.191 1.191
16.833 4.61 0.657 1.201 1.204 I
16.712 4.614 0.652 1.221 1.214
16.591 4.618 0.647 1.221 1.185
\ 16.453 4.623 0.642 1.114 1.609 j
16.206 4.627 0.632 2.492 2.033
15.959 4.631 0.622 2.492
Table A. 1.2 Sample calculation of the transition analysis
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II Max response I 25.33 II
I  Min response | 0.553 1
Table A. 1.2 Maximum and minimum conductivity data
An example of the calculation of the rate of change of the response with volume 
(<dR/dV) is given in Equation A. 1.2 using the values in Table A. 1.1 highlighted in 
blue.
dR 0.692-0.683 = 2.270 = ------------------
dV  4 .590-4.586
Equation A. 1.2.
An example of a moving average calculation is given in Equation A. 1.3 using data 
from Table A. 1.1. highlighted in grey.
moving average = 1.364 = 
Each moment is calculated as follows
1.746 + 1.170 + 1.181
M0 =1.00= f Va— dV  
0 J dV
M, =  4.75 = fV ' — dV  
3 dV
M , =22.65= f r 2—  dV  
2 J dV
Equation A. 1.4
Equation A. 1.5 
Equation A. 1.5 
Equation A. 1.6
The variance, o is calculated from moments 1,2 & 3 as follows.
M.2 _ 22.65 ( 4.75'
1.00 1.00
0.150 Equation A. 1.7
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Appendix 2 -  Elution profile correction process sample calculations
Protein
cone
(mg/mL)
Figure A.2.1.
USD elution profile 
with peak area =10, 
retention volume = 5 
distance, x = 2
Retention volume
Column volumes
Figure A.2.1 -  Original elution profile generated by USD column
The following ratio from the conductivity transitions is then used to correct the data 
points around the retention volume,
normalized variance from large-scale : normalized variance from USD scale
In this example, this ratio would be
7.11:1
The distance each data point to the retention volume would, therefore, be decreased 
by a factor of V7.11 = 2.66 from 2 to 0.75 as shown in Figure A.2.2.
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Protein
cone
(mg/mL)
Figure A.2.2.
New elution profile 
with peak area = 7, 
retention volume = 5 
distance, x = 0.75.
Column volumes
Figure A.2.2. Correction for additional zone broadening
Correction in this way leads to a decrease in the elution peak area. The area must be 
maintained so while the peak shape is maintained the area is increased as shown in
Figure A.2.3.
Protein
cone
(mg/mL)
Figure A.2.3.
New elution profile 
with peak area =10, 
retention volume = 5.
Column volumes
Figure A.2.3. Maintaining peak area.
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It is easy to see from Figure A.2.3 how this can be achieved by looking at either half 
of the elution peak around the retention volume. The area under the curve, 
determined by integration, is increased until it matches that of the original elution 
profile. The angle between the vertical line down the centre of the modified elution 
profile (representing the retention volume) and each data point is maintained as the 
area of the corrected peak is increased.
The final correction is the adjustment of the peak retention volume using the ratio 
from the transition analysis,
normalized retention volume (large-scale)normalized retention volume (USD scale) 
In this example, this ratio would be
1.25:1
The retention volume of each data point is then reduced by a factor of 1.25 as shown 
in Figure A.2.4.
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Protein
cone
(mg/mL)
Figure A.2.4.
Final elution profile 
with peak area =10, 
retention volume = 4 
and variance = 0.75.
Column volumes
Figure A.2.4 Correction of retention volume.
201
Chapter 1
Nomenclature
9 (rads) disc half conical angle 
co (s'1) angular velocity
2*(m ) equivalent centrifuge settling area of the disc stack centrifuge
Z\ab (m ) equivalent centrifuge settling area of the laboratory centrifuge
A p  (kg m'3) fluid/solid density difference
p (Pa s) dynamic viscosity
Cds (-) correction factor for disc stack centrifuge
Chb (-) correction factor for laboratory centrifuge
d  (m) particle diameter
2 (m  /s) flow rate through continuous centrifuge 
r (m) settling radius 
ri (m) disc inner radius 
Ri (m) inner radius 
ri (m) disc outer radius 
R2 (m) outer radius
t(iab) (s) time of laboratory centrifuge run
u (m s"1) linear fluid velocity
V (m3) volume of process fluid in centrifuge tube
vc(r) (m s'1) settling velocity of a particle
x  (-) fraction of overall centrifugation time for deceleration
y  (-) fraction of overall centrifugation time for acceleration
z (-) number of active discs
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Chapter 2
c correction factor for non-ideal flow patterns 
ODo optical density of a well-spun sample at 550nm 
ODf optical density of the feed at 550nm 
ODs optical density of the supernatant at 550nm
Chapter 3
Chapter 4
e (-) bed void fraction
ci2 (m2) band broadening
2 2o col (m ) column internal broadening 
(m ) band broadeneing due to finite sensing volume of a detector 
g^  (m ) extra column broadening 
ot (m ) tubing band broadening
GL i * (“) total normalized band broadening, o?otal* = o l tal/V*
GLai (m2) total band broadening,
Tdead (m2) exponential contribution of dead volumes to band broadening
Tei (m2) exponential contribution of the amplifier and recorder to band broadening
Dm (mm2 s '1) molecular diffusion coefficient
HETP (pm) Height equivalent to a theoretical plate
k (-) moment number
L (m) bed length
M(-) moment
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N  (-) number o f  plates
3 1Q (m s ' ) volumetric flow rate 
r (m) column radius 
R (-) response signal 
tR (s) retention time 
v (m s _1) linear flow rate 
Vc (m3) column volume 
Vd (m3) detector volume 
Kiead- (m ) dead volume 
Vex (m ) extra-column volume 
Vr (m ) retention volume 
VR (-) normalised retention volume, V* = VR jVc 
z  (m) distance traveled by solute
Chapter 5
e (-) interstitial bed porosity 
s0 (-) gravity settled bed porosity.
X (-) bed compression.
XCri (-) critical bed compression.
p (Pa s) dynamic viscosity
dp (pm) resin particle diameter
K0 (-) empirical constant (Blake-Kozeny equation).
L0 (m) is the gravity settled bed height
Lcri (m) critical bed height
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ucri (cm h"1) critical flow velocity 
Vc (mL) column bed volume 
Vco (mL) gravity settled bed volume
List of Abbreviations
BSA -  Bovine Serum Albumin
CFD -  Computational Fluid Dynamics
CHO -  Chinese Hamster Ovary cells
CV -  Column Volume
DHFR -  Dihydrofolate Reductase
ELISA -  Enzyme Linked Immuno Sorbent Assay
FDA -  Food and Drug Administration
GS -  Glutamine Synthatase
HAMA -  Human Anti-Murine Antibodies
HPLC -  High Performance Liquid Chromatography
IEF -  Isoelectric Focussing
MAb -  Monoclonal antibody
MSX -  Methionine Sulphoximine
MTX -  Methotrexate
OD -  Optical Density
RPM -  Rotations Per Minute
TNF -  Tissue Necrosis Factor
USD -  Ultra scale-down
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